Ask the Scholar

Document scope · 1 page
doc
Scholar
Ask about this object, its catalog metadata, its source description, or the page inventory. For page-specific OCR and visual context, open one of the page chats.

Scholar Source Context

Document identity
localId
55031105
label
AIDS [Acquired Immune Deficiency Syndrome] [Folder 2] [2]
core
doc
dtoType
document
pageCount
1
Source metadata
Source extras
naId
55031105
levelOfDescription
fileUnit
otherTitles
2068127-20130534S-050-009-2022
recordType
description
ocrSource
nara-archive
Single page context
seq
1
pageIndex
0
type
document
mediaId
8556d11a15e53c58
ocrText
Withdrawal/Redaction Sheet Clinton Library DOCUMENT NO. SUBJECT/TITLE DATE RESTRICTION AND TYPE 001. memo Sandra Thurman to the President re: Report on Presidential Mission 04/21/1999 P1/b(1) Looking at Children Orphaned by AIDS in sub-Sahara Africa (6 pages) COLLECTION: Clinton Presidential Records First Lady's Office Melanne Verveer OA/Box Number: 20018 FOLDER TITLE: AIDS [Acquired Immune Deficiency Syndrome] [Folder 2] [2] 2013-0534-S ry1535 RESTRICTION CODES Presidential Records Act - [44 U.S.C. 2204(a)] Freedom of Information Act - [5 U.S.C. 552(b)] P1 National Security Classified Information [(a)(1) of the PRA] b(1) National security classified information [(b)(1) of the FOIA] P2 Relating to the appointment to Federal office [(a)(2) of the PRA] b(2) Release would disclose internal personnel rules and practices of P3 Release would violate a Federal statute [(a)(3) of the PRA] an agency [(b)(2) of the FOIA] P4 Release would disclose trade secrets or confidential commercial or b(3) Release would violate a Federal statute [(b)(3) of the FOIA] financial information [(a)(4) of the PRA] b(4) Release would disclose trade secrets or confidential or financial P5 Release would disclose confidential advice between the President information [(b)(4) of the FOIA] and his advisors, or between such advisors [a)(5) of the PRA] b(6) Release would constitute a clearly unwarranted invasion of P6 Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA] personal privacy [(a)(6) of the PRA] b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA] C. Closed in accordance with restrictions contained in donor's deed b(8) Release would disclose information concerning the regulation of of gift. financial institutions [(b)(8) of the FOIA] PRM. Personal record misfile defined in accordance with 44 U.S.C. b(9) Release would disclose geological or geophysical information 2201(3). concerning wells [(b)(9) of the FOIA] RR. Document will be reviewed upon request. AIDS Convening September 7, 1999 Briefing Book I- Briefing Memo II - Participants 1 - List 2- - Bio of Dr. Peter Piot and fact sheet on UNAIDS 3 - - "Bristol Myers Heeds Calls to Bolster War Against HIV in Africa" - - Wall Street Journal 4 - - "Gates to Give Away Fortune" - UPI 5 - - "The Global HIV/AIDS Epidemic" - The Surgeon General III - Agenda IV - Invite Letter V - - Background Information 1 - - AIDS in Africa is a Serious Crisis 2- - Press Release on Administration Initiative 3 - - Backgrounder on Administration Initiative and Q&A 4 - - Wolfensohn Letter to the President 5 - - USTR Paper in Intellectual Property Rights 6 - - "Helping the Poorest" - The Economist Editorial 7- - Statement and Fact Sheet on Cologne Debt Relief Agreement 8 - - "Helping the Poorest" - The Economist, Jeffrey Sachs article 9 - - "Balms for the Poor" - The Economist 10 - "Orphans of the Virus" - The Economist 11 - "Drugs for AIDS in Africa"- New York Times Editorial 12 - "Facing a Global AIDS Crisis"- - The Washington Post 13 - "A Global Disaster" - The Economist 14 - "In Africa, a Deadly Silence About AIDS is Lifting" New York Times 15 - - HIV/AIDS Prevalence Rates for Sub Saharan Africa VI- Talking Points THE WHITE HOUSE WASHINGTON September 3, 1999 MEMORANDUM TO THE FIRST LADY FROM: Sandra Thurman, Director, Office of National AIDS Policy SUBJECT: Need for an Enhanced Response to the AIDS Crisis in Africa and Around the World Summary In the next decade, 40 million children will be orphaned as a result of losing one or both parents to AIDS. AIDS is not just taking lives, it is threatening economics, stability, and civil society. AIDS is wiping out decades of progress on a variety of development fronts, including per capita GNP, infant mortality, and life expectancy. Leadership and investment can help, and has helped, to turn the tide. Political support for a more aggressive United States response is building. As goes Africa, so will go India, Asia, and the new Soviet states, and by 2005, more than 100 million people worldwide will have been infected with HIV. Background On World AIDS Day last year, the President highlighted the growing global tragedy of children orphaned by AIDS in sub-Saharan Africa. At that time, he directed me to lead a fact-finding mission to the region and to report back to you with recommendations for productive action. From March 27 through April 5, I led a Presidential Delegation to Zambia, Uganda, and South Africa. I was accompanied by Representatives Jackson-Lee, Kilpatrick, and Lee, and assorted senior staff. We were also joined by a select group of individuals from outside of government including Mayor Dinkins, Bishop Felton May, and William Harris. [Attachment A: Manifest] The goals of the trip were: to heighten awareness, promote leadership, and identify promising interventions. In Zambia and Uganda, we met with the Presidents and a variety of government ministers (health, welfare, community development, finance, etc.). In each country we visited a host of community-based programs serving children and families affected by AIDS, and talked with donors, experts, providers, and consumers about actions taken, lessons learned, and barriers to further progress. On July 19, 1999 the White House released the subsequent report to the President on the mission and our proposed plan of action (press release attached). The new initiative includes a request to the Congress for an additional $100 million to combat AIDS primarily in Africa. This is the largest-ever budget increase in the global battle against AIDS and more than doubles the United States efforts. In addition to the $100 million, the initiative includes a variety of strategic opportunities for challenging other partners to join in an enhanced effort starting with your meeting with key stakeholders on Tuesday. Others include: - Business Leaders Meeting - The Department of Commerce will facilitate a meeting of business leaders active in Africa to encourage them to increase their efforts in the battle against AIDS. This is tentatively scheduled for early November and the Vice President has expressed interest in participating. - Labor Leaders Meeting - The Department of Labor, led by Secretary Herman, and the AFL-CIO will co-host a meeting of US and African labor leaders to determine ways to expand existing programs which use trade unions to provide outreach and HIV/AIDS education (Note: In many parts of South Africa one in four mine workers in HIV-positive). - Religious Leaders Summit - The Office of National AIDS Policy will facilitate a meeting of African, American and other religious leaders to discuss ways to more effectively engage communities of faith in the fight against AIDS. Several prominent religious leaders have tentatively committed to participate including Reverends Jesse Jackson, Leon Sullivan, Andrew Young and Archbishop Desmond Tutu. - UN Conference on Children Orphaned by AIDS - On December 1,1999 (World AIDS Day), the United Nations in conjunction with the National Black Leadership Commission on AIDS (chaired by David Dinkins), The White House Office of National AIDS Policy, The Magic Johnson Foundation and a variety of NGO's will hold a conference to focus attention on the growing number of children orphaned by AIDS. You have been asked to deliver a keynote address. Attached please find the Memoranda to the President on this issue for your review. I welcome the opportunity to discuss this with you further, and greatly appreciate your continued support and leadership on behalf of people living with HIV/AIDS both at home and abroad. 2 Withdrawal/Redaction Marker Clinton Library DOCUMENT NO. SUBJECT/TITLE DATE RESTRICTION AND TYPE 001. memo Sandra Thurman to the President re: Report on Presidential Mission 04/21/1999 P1/b(1) Looking at Children Orphaned by AIDS in sub-Sahara Africa (6 pages) COLLECTION: Clinton Presidential Records First Lady's Office Melanne Verveer OA/Box Number: 20018 FOLDER TITLE: AIDS [Acquired Immune Deficiency Syndrome] [Folder 2] [2] 2013-0534-S ry1535 RESTRICTION CODES Presidential Records Act - [44 U.S.C. 2204(a)] Freedom of Information Act - [5 U.S.C. 552(b)] P1 National Security Classified Information [(a)(1) of the PRA] b(1) National security classified information [(b)(1) of the FOIA] P2 Relating to the appointment to Federal office [(a)(2) of the PRA] b(2) Release would disclose internal personnel rules and practices of P3 Release would violate a Federal statute [(a)(3) of the PRA] an agency [(b)(2) of the FOIA] P4 Release would disclose trade secrets or confidential commercial or b(3) Release would violate a Federal statute [(b)(3) of the FOIA] financial information [(a)(4) of the PRA] b(4) Release would disclose trade secrets or confidential or financial P5 Release would disclose confidential advice between the President information [(b)(4) of the FOIA] and his advisors, or between such advisors [a)(5) of the PRA] b(6) Release would constitute a clearly unwarranted invasion of P6 Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA] personal privacy [(a)(6) of the PRA] b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA] C. Closed in accordance with restrictions contained in donor's deed b(8) Release would disclose information concerning the regulation of of gift. financial institutions [(b)(8) of the FOIA] PRM. Personal record misfile defined in accordance with 44 U.S.C. b(9) Release would disclose geological or geophysical information 2201(3). concerning wells [(b)(9) of the FOIA] RR. Document will be reviewed upon request. ATTACHMENT A PRESIDENTIAL MISSION TO AFRICA MARCH 27, 1999 - APRIL 5, 1999 MEMBERS OF CONGRESS Rep. Carolyn Kilpatrick, Foreign Operations Subcommittee, Appropriations, Congressional Black Caucus Rep. Barbara Lee, Africa Subcommittee, International Relations, Congressional Black Caucus Rep. Sheila Jackson Lee, Founder and Chair, Congressional Children's Caucus, Congressional Black Caucus CONGRESSIONAL STAFF Bruce Artim, Health Staff, Senator Hatch Mary Lynn Qurnell, Legislative Assistant, Senator Helms Stephanie Robinson, General Counsel, Senator Kennedy Carolyn Bartholomew, Legislative Director, Rep. Pelosi, Minority Staff, Foreign Operations Subcommittee, Appropriations NON-GOVERNMENTAL PARTICIPANTS William Harris, President, Children's Education and Research Institute Bishop Felton May, General Board of Global Ministries, United Methodist Church David Dinkins, Chair, Black Leadership Coalition on AIDS Dr. Jacob Gayle, World Bank Rory Kennedy, Documentary filmmaker Nick Doob, Documentary filmmaker ADMINISTRATION OFFICIALS Sandy Thurman, Director, Office of National AIDS Policy Michael Iskowitz, Consultant, USAID Dr. Paul DeLay, Director, HIV/AIDS Programs, USAID Maria Sotiropoulos, Protocol Officer, State Department Phil Drouin, Africa Bureau, State Department MILITARY PERSONNEL Lt. Commander James Erskine Dr. Anthony Barile Brenda Geist, Director Congressional Travel ATTACHMENT B Peter D. Hart Research Associates, Inc. 1724 Connecticut Avenue, N.W Washington, D.C. 20009 202-234-5570 202-232-8134 FAX Increase U.S. Assistance to Fight AIDS in Africa 54% 29% 17% Favorable Neutral/not sure Unfavorable Peter D. Hart Research Associates surveyed 1,411 registered voters, including 310 African Americans, by telephone between February 20 and 26, 1999, for the Children's Research and Education Institute. American voters view the spread of AIDS in Africa as a serious problem. Although many voters have not heard much about the issue, they nonetheless believe that it is likely to have an impact here at home. A majority of Americans have a favorable view of a proposal to increase U.S. government assistance for international AIDS programs in Africa. The spread of AIDS in Africa is viewed as a serious problem by two-thirds (67%) of American voters, with 45% saying that it is an extremely serious problem and an additional 22% describing it as a quite serious problem. The same proportion (67%) believe that it is false to say that the global AIDS crisis is coming under control. In addition, three-quarters (75%) of voters believe that the AIDS epidemic in Africa will affect people in the United States. Although the issue is important, only 19% of voters say that they have read or heard a lot about it. Nearly half (48%) say that they have heard little or nothing about it. A 54% majority are favorable to a proposal to increase government assistance for international efforts to fight the spread of AIDS in Africa. Only 29% are unfavorable. - An overwhelming 83% majority of African Americans are favorable (55% strongly favorable), and only 10% are unfavorable. Support for greater assistance increases when it is placed in the context of an international effort. Three-quarters (76%) of voters say that they would be more likely to support assistance to help Africa deal with the AIDS epidemic if they knew that it would be a part of a larger international effort with Europe, Japan, and other countries doing their share. Study #5408 CREI/Social Issues Interviews: 1411 voters, including 310 African Americans Dates: February 20-26, 1999 AIDS in Africa I'm going to mention some different issues, and I'd like to find out how serious a problem you consider each one to be in our country today. For each one, please tell me whether you consider it to be an extremely serious problem, a quite serious problem, a somewhat serious problem, or not that serious a problem. Extremely Quite Somewhat Not That Serious Serious Serious Serious A Not Problem Problem Problem Problem Sure The spread of AIDS in Africa 45 22 13 8 12 Now I'm going to read you another list of statements. For each statement, please tell me whether you're sure it's true, think it's probably true, think it's probably false, or are sure it's false. Think Think It's It's Sure Sure Probably Probably It's Not It's True True False False Sure The global AIDS crisis is coming under control 2 20 37 30 11 Now, I'm going to mention several proposals and I'd like to get your reaction. For each proposal I read, please tell me whether your reaction is very favorable, somewhat favorable, neutral, somewhat unfavorable, or very unfavorable. Very Somewhat Somewhat Very Not Favorable Favorable Neutral Unfavorable Unfavorable Sure Increasing U.S. government assistance for international efforts to fight the spread of AIDS in Africa ALL VOTERS 23 31 15 14 15 2 African Americans 55 28 6 5 5 1 How much have you heard or read about the issue of AIDS in Africa - a lot, some, just a little, or not very much? ** ALL African VOTERS Americans Heard/Read A lot 19 31 Some 32 28 Just a little 22 22 Have not heard/read very much 23 16 - Heard/read nothing (VOL) 3 1 Not sure 1 2 ** Asked of one-half the respondents (FORM B). CREI/Social Issues Interviews: 1411 voters, including 310 African Americans Dates: February 20-26, 1999 AIDS in Africa Do you think that the AIDS epidemic in Africa will affect people in the United States, or not? ** ALL African VOTERS Americans Yes, will affect people in the U.S 75 83 No, will not affect people in the U.S 16 10 Not sure 9 7 ** Asked of one-half the respondents (FORM B). If you knew that the U.S. assistance to help Africa deal with the AIDS epidemic would be part of a larger international effort with Europe, Japan, and other countries doing their share, would you be much more likely to support it, somewhat more likely to support it, or no more likely to support it? ** ALL African VOTERS Americans Much more likely to support 37 49 Somewhat more likely to support 39 35 No more likely to support 20 12 Less likely to support (VOL) 1 - Not sure 3 4 ** Asked of one-half the respondents (FORM B). Study #5408 CREI/Social Issues Interviews: 1411 voters, including 310 African Americans Dates: February 20-26, 1999 AIDS in Africa Now I am going to read you some reasons that people might give for supporting increased U.S. government assistance to fight the spread of AIDS in Africa For each one, please tell me how convincing a reason it is to support increased assistance - very convincing, fairly convincing, only somewhat convincing, or not that convincing. ** Only Very Fairly Somewhat Not That Not Convincing Convincing Convincing Convincing Sure We all live on one planet, and the whole world benefits from fighting the spread of AIDS-if the epidemic has spread that much in Africa, we are fooling ourselves if we think that it won't affect the U.S.-it will, unless we do something now ALL VOTERS 44 14 21 16 5 African Americans 67 12 11 7 3 The AIDS epidemic is creating millions of orphans that are overwhelming the capacities of orphanages and churches, and filling the streets of many African cities. An estimated forty million children will lose a parent to AIDS by 2010 ALL VOTERS 40 15 23 15 7 African Americans 56 18 17 6 3 5 24-99 THE WHITE HOUSE WASHINGTON l'dlinto May 21, 1999 (c Bruhtown- MEMORANDUM TO THE PRESIDENT CC: NSC/sandy FROM: CC Gene S Sandra L. Thurman, Director, Office of National AIDS Policy ) a Back to me SUBJECT: AIDS in Africa - Response to Your Request for Additional Information Idlike to helpre this Thank you for calling me in Ghana and for reiterating your concern about the AIDS emergency in Africa and the need for an invigorated US effort. As a follow-up to our conversation, this memorandum provides additional information that seeks to put the issue of AZT for pregnant women in the broader context of the AIDS pandemic in Africa. AIDS is a plague of biblical proportion Thanks to the commitment of Rev. Leon Sullivan, for the first time, the African African- American Summit focused much needed attention on the issue of AIDS in Africa and acknowledged the following bleak realities: AIDS buries more than 5,500 people a day in Africa and that number will more than double in the next few years. The WHO just declared AIDS the leading cause of death among all people of all ages in Africa, and each day, an additional 11,000 people become HIV infected. Most of these new infections are among young people, under the age of 25. By 2005, more than 100 million people worldwide will be HIV-positive. AIDS is leaving a generation of children in jeopardy. In many countries, between one-fifth and one-third of all children have already been orphaned by AIDS, and the worst is yet come. Within the next decade more than 36 million children will be orphaned by AIDS in sub-Saharan Africa, and this tragedy will continue to grow for at least another 30 years. AIDS is wiping out decades of steady progress in development, doubling infant mortality, tripling child mortality, and slashing life expectancy by 20 years or more. AIDS is devastating economic growth, threatening political and regional stability, and stands a serious obstacle to the realization of your new partnership with Africa, again celebrated in Ghana. copied The combination of leadership and resources can turn the tide. POTUS In our battle against AIDS, Uganda is the model for success in the developing world. President NSC we Museveni has been a strong and effective AIDS leader, and has created an environment ripe for Berger change. In response, the US has invested more than $50 million on AIDS in Uganda over a ten- Sperling Podista Thurmar year period. Through this combination of leadership and sustained resources, Uganda has cut the rate of HIV by more than half, and organized model AIDS care programs. As an essential component of your new partnership with Africa, we need to help cultivate AIDS leadership among more African leaders, and we need to help enhance the overall investment in the war on AIDS to a level that meets the magnitude of this crisis. On the leadership front, we are beginning to see positive movement. As the realities of the AIDS become increasingly unavoidable, a growing number of African leaders are stepping up to the plate. However, the resources currently dedicated to winning this war, from both host governments and donors, are All grossly inadequate. As I said in my previous memorandum, in the face of a 300% rise in annual HIV incidence and an AIDS explosion in sub-Saharan Africa, the USAID global AIDS budget has remained essentially stagnant since 1993 Other donors have followed suit. Without a dramatically enhanced response, we will lose this war. Our Global AIDS Emergency Working Group is exploring three strategies for increasing the availability of resources to begin to meet the ever growing global AIDS crisis. First, we are looking at an increase in the USAID global AIDS budget. In this context, it is important that this increase be new money and not taken from other essential development accounts. Health, education, child-survival, and micro-finance are all interconnected components of a comprehensive human investment and AIDS strategy. Shifting money from one account to another will not improve our collective effort. Second, we are looking at an approach to debt relief that not only considers a debtor nation's economic policy but its strong commitment to investing in human capacity, particularly HIV and AIDS. Countries such as Côte d'Ivoire, : Kenya, Nigeria, South Africa, and Zambia all hold considerable US debt and have a serious and growing AIDS emergency. Third, we are looking at public-private partnerships. Finding ways to increase access to AZT for HIV-positive pregnant women is an integral part of an invigorated response to AIDS in Africa. With additional resources, the US can partner with host governments and other donors to promote an aggressive strategy on four fronts including: containing the AIDS pandemic, providing home and community-based AIDS treatment and support, caring for children orphaned by AIDS, and gearing up for the long haul through health infrastructure and capacity development. In the context of containing the AIDS pandemic, developing ways to prevent mother-to-child transmission that are workable in Africa is a high priority. In Africa today, for every ten children born to HIV-positive mothers, two become infected during delivery, one becomes infected through breast-feeding, and seven remain HIV-negative. A "short course" of AZT at the time of birth and for a week following has been found to reduce the number of babies who become HIV- positive during delivery by nearly 40%. This is extremely encouraging news. However, a host of additional issues need to be explored and addressed before this knowledge can be effectively implemented. USAID is now devoting $6 million to answering key questions surrounding the use of AZT to reduce mother-to-child transmission of HIV in the developing world. For example, to keep babies HIV-negative, mothers who receive AZT during delivery should not breastfeed. However, in many areas of sub-Saharan Africa, babies are as likely to die from diarrhea resulting from misuse of formula as they are from AIDS. The lack of health care infrastructure is also a serious issue. More than 95% of pregnant women do not know they are HIV-positive and currently lack access to vital testing and counseling services needed to find out. Further, in many areas, most women deliver their children with the assistance of midwives in their homes, or in makeshift clinics unequipped for AZT interventions. Finally, the AIDS stigma is so great in places like South Africa, that fear and denial keep pregnant women from discovering their status, even if they have the option. Recently a woman in South Africa with HIV went public with her status and was stoned to death by her neighbors, and countless others have been left destitute on the street with their children after their husbands found out they were HIV-positive. As we begin to address these issues, we will increase our ability to move forward with the implementation of an AZT intervention. The cost of AZT remains a serious concern. Even with a price reduction from Glaxo Wellcome, AZT is expensive, particularly by African standards, and health planners face difficult choices over the best use of scarce resources. In South Africa, Health Minister Zuma has opposed providing AZT to pregnant women because it cannot be made available to all who need it and because she believes that other approaches are more cost effective. For example, she believes that it is better to focus on keeping women of childbearing age HIV-negative, thereby not only saving children from becoming infected but from becoming orphaned as well. In addition, this AZT discussion has been caught up in the debate over US policy on compulsory licensing, and South Africa's desire to produce AZT at a more affordable price. It is for these reasons that the delivery of AZT to pregnant women is one prong of a multifaceted approach to respond to AIDS : in Africa. I welcome the opportunity to discuss this with you further, and hope to have a report to you on AIDS in Africa, including recommendations from the Global AIDS Emergency Working Group, in early June. II. Participants 1- List 2- Bio of Dr. Peter Piot and fact sheet on UNAIDS 3- "Bristol Meyers Heeds Calls to Bolster War Against HIV in Africa" - Wall Street Journal 4- "Gates to Give Away Fortune" - UPI 5- "The Global HIV/AIDS Epidemic" - The Surgeon General AIDS Convening September 7, 1999 Participants List Administration First Lady Hillary Rodham Clinton Secretary Donna Shalala Department of Health and Human Services The Honorable David Satcher Surgeon General Secretary Lawrence Summers Department of the Treasury Administrator Brady Anderson US Agency for International Development The Honorable Leon Fuerth Assistant to the Vice President for National Security Affairs The White House The Honorable Sandy Thurman Director National AIDS Policy Office The White House Ms. Gayle Smith Senior Director for African Affairs National Security Council The White House Under Secretary Frank Loy Under Secretary for Global Affairs Department of State Melanne Verveer Assistant to the President and Chief of Staff to the First Lady The White House Dr. Ken Bernard International Health Affairs National Security Council The White House Multinational Organizations Mr. James Wolfensohn President World Bank Ms. Jan Piercy The Executive Director of the United States The World Bank Dr. Peter Piot Executive Director Joint United Nations Program on HIV/AIDS Foundations Dr. Timothy Evans Team Director for Health Services The Rockefeller Foundation Mr. Aryeh Neier President Soros Foundations Network Open Society Institute Mr. Stewart Burden Senior Program Officer The John D. and Catherine T. MacArthur Foundation Dr. Gordon Perkin President of PATH William H. Gates Foundation Dr. Drew Altman President and CEO Kaiser Family Foundation Corporations/Others Mr. Charles Heimbold Chairman and Chief Executive Officer Bristol Myers Squibb Mr. Robert Johnson Chairman and CEO Black Entertainment Television Observers B.A. Rudolph Chief of Staff to the Administrator Agency for International Development Paul Delay Agency for International Development Duff Gillespie Agency for International Development Dr. Jim Sherry United Nations Joint Program on HIV/AIDS Mr. Eduardo Doryan Vice President and Head of Network The World Bank Ms. Debrework Zewdie Lead Specialist, Population The World Bank Timothy Geithner Under Secretary for International Affairs Department of the Treasury William Schuerch Deputy Assistant Secretary for International Development, Debt and Environmental Policy Department of the Treasury Ms. Debrah Lee President and COO Black Entertainment Television Mr. Ken Weg Vice Chairman Bristol Myers Squibb Dr. Seth Berkley President International AIDS Vaccine Initiative The Rockefeller Foundation Mr. Terry Anderson Executive Director of Public Policy National Association of People with AIDS Mr. Paul Boneberg Director Global AIDS Action Network Ms. Diane Graham Special Assistant for Global Affairs State Department Richard Socaridies Special Assistant to the President and Senior Adviser for Public Liaison Office of the Public Liaison The White House UNAIDS UNICEF UNDP UNFPA UNESCO WHO WORLD BANK Joint United Nations Programme on HIV/AIDS PETER PIOT Executive Director, UNAIDS Biographical information Peter Piot was appointed Executive Director of the Joint United Nations Programme on HIV/AIDS (UNAIDS) and Assistant-Secretary-Genera of the United Nations on 12 December 1994. Dr Piot joined UNAIDS from a position as Director of the Division of Research and Intervention Development at the Global Programme on AIDS of the World Health Organization. Dr Piot had previously served hom 1980 10 1992 as Professor of Microbiology and Head of the Department of Infection and Immunity at the Institute of Tropical Medicine in Antwerp, Belgium. During this period, hc also launched and expanded a series of collaborative projects in Burundi, Côte d'Ivoire, Kenya, Tanzania and Zairc, including "Projet SIDA" in Kinshasa, Zaire, which was the first international HIV/AIDS project to be established in the developing world. Dr Piot was Associate Professor of Public Health at the Free University of Brussels from 1989 to 1992, and Associate Professor of Microbiology at the University of Nairobi from 1986 to 1987. From 1978 to 1979, he was Senior Hellow at the University of Washington, where he carried out research on infections diseases. During an investigation into an outbreak of haemorrhagic fever in northern Zaire in 1976. he became co-discoverer of the Ebola virus. He served as the President of the International AIDS Society from 1991 to 1994. Prior to joining UNAIDS, he was editor of AIDS, the leading scientific journal in its field. Dr Piot qualified as a Doctor of Medicine at the University of Ghent in 1974 and received a Doctorate in Microbiology from the University of Antwerp in 1980. He has received many awards for scientific achievement and public service, and has published over 500 articles and 14 books, mostly on issues related to AIDS, scxually transmitted diseases and women's reproductive health. Hc was awarded a baronetcy by II.M. King Albert II of Belgium in 1995. Dr Piot was born in Leuven, Belgium in 1949. 14.01.99 Doc #9496 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel: (+4122) 791,3666 Fax: (+4122) 791.4187 e-mail: [email protected] 500 Relatton Jre/sptaun 86 sv TOL +1122 FAX 15:35 ner 66, TO/VI Peter Fiot. Executive Director, Joint United Nations Programme on HIV/AIDS (UNAIDS). For information, please contact UNAIDS, Geneva, Switzerland. Phone: (+4122) 791 3556, Fax: (+4122) 791 4187. e-mail UNAIDSIWHO ch. internet http://158.232 20 3/unaids.htm UNAIDS Please give credit to UNAIUS/Yosn: Shimizu. 000 7 É поттятех RR st TRL ZZID+ YVH 15:35 ner 66. TO/VI UNAIDS FACT SHEET UNICEF UNDP UNIPA UNESCO WHO WORLD BANK Joint United Nations Programme on HIV/AIDS November 1998 UNAIDS The HIV/AIDS epidemic continues to progress. Each day. some 16 000 people are newly infected with HIV. the virus that causes AIDS. UNAIDS estimates that more than 33 million people are currently living with HIV/AIDS, over 90% of whom live in the developing world. Meeting the complex long-term challenge of HIV/AIDS calls for an expanded response. Direct health interventions and action to influence the immediate aspects of AIDS prevention and care must be pursued and intensified, while innovative action must be undertaken to address the broader context of the epidemic, including its socio-economic causes and consequences. A major reform In recognition of this concern, the Joint United Nations Programme on HIV/AIDS (UNAIDS) was established in January 1996. UNAIDS is a co-sponsored programme that brings together the United Nations Children's Fund (UNICEF), the United Nations Development Programme (UNDP), the United Nations Population Fund (UNFPA), the United Nations Educational, Scientific and Cultural Organization (UNESCO), the World Health Organization (WHO) and the World Bank in a common effort against the epidemic. It is the first programme of its kind in the UN system. a small programme with a large outreach and the potential to lever significant resources and action through the creation of strategic partnerships. The UNAIDS cosponsors bring to this joint endeavour complementary mandates and multisectoral expertise, ranging from education and socio-economic development to women's reproductive health. They are committed to joint planning and action, giving UNAIDS a "cooperative advantage" that translates into greater synergy and efficiency. Benefits include more effective advocacy, more effective use of UN system resources through the sharing of COSTS, and greater coherence in United Nations support to national AIDS programmes. Mission of UNAIDS As the main advocate for global action on HIV/AIDS, UNAIDS leads, strengthens and supports an expanded response aimed at preventing the transmission of HIV, providing care and support, reducing the vulnerability of individuals and communities to HIV/AIDS, and alleviating the impact of the epidemic. 1 20. ovenue Appia CH-1211 Geneva 27 Switzerland Tel: (+4122) 791,3666 Fax: (+4122) 791.4187 e-mail: [email protected] Z00 Relatton 86 sv TBL +1122 PAYA nar 66. TO/VI Guiding principles of UNAIDS Long-term response: HIV/AIDS requires a long-term sustainable response, including coping capacity on the part of Individuals and communities. UNAIDS helps to strengthen national capacity for action ranging from prevention and care to impact alleviation. Technical soundness: Action In response to the HIV/AIDS epidemic must be not only expanded but also improved in quality through the identification and use of technically sound policies, strategies, tools and approaches. Focus on vulnerability: An effective response requires societal and structural change to reduce the vulnerability of women, young people, migrants, drug users, sexual and ethnic minorities and other population groups. Support, not coercion: A supportive social; political and legal environment helps individuals exercise their responsibilities to protect themselves and others from HIV infection. Human rights: People are entitled to enjoy all human rights without discrimination, including discrimination based on HIV infection status. These include the right to health, travel and privacy, the right to freedom from sexual violence and coercion, and the right to the information and means to prevent infection. Participation and partnership: A multisectoral response to HIV/AIDS can best be achieved through partnership. National autonomy: It is a national responsibility to design, implement and coordinate the response to HIV/AIDS at the country level. The role of external partners, including UNAIDS, is to support and build on national action. Complementarity: Rather than undertaking itself what can be or is already being done by others. UNAIDS attempts to facilitate these efforts and to fill gaps in action and research. Global and local impact At the global level, UNAIDS is the AIDS programme of the six cosponsors, carrying out the roles of policy development and research, technical support, advocacy, and coordination. At the same time, the six cosponsoring organizations integrate HIV/AIDS-related issues and UNAIDS policies and strategies into their ongoing work. At the country level, UNAIDS can best be seen as the sum of AIDS-related activities carried out by its six cosponsors with the backing of UNAIDS technical guidance and resources. In countries where some or all of the cosponsors are present, their representatives meet regularly in a special "Theme Group" to jointly plan, programme and evaluate their AIDS-related activities. In addition, UNAIDS has staff known as Country Programme Advisors posted in selected countries to support the Theme Groups on HIV/AIDS, to strengthen cooperation with national partners, and to provide technical support. Important partners in national AIDS activities include governments (through both political leadership and the relevant ministries): community-based organizations; nongovernmental organizations (NGOs): the private sector; academic and research institutes; religious and other social and cultural institutions: and people living with HIV/AIDS. Governance UNAIDS is the first programme of the United Nations system to have NGO representation on its governing body. The Programme Coordinating Board (PCB) is comprised of representatives of 22 Member States of the UN system, (including both donor and recipient countries), of the six cosponsors, of NGOs and people living with HIV/AIDS. 2 003 unaids/exr Relation 14/01 15:31 JEU 88, FAX +1122 791 18 : Strategic areas Country support: The overriding goal of UNAIDS at country level is to enhance national capabilities to mount an expanded, multisectoral response to HIV/AIDS. Priority is given to nationally determined needs, in particular those of developing countries and economies in transition. International best practice: Gamering practical experience from around the world. UNAIDS identifies sound policies and strategies that have proven to be effective what is known as "intemational best practice". These approaches are analysed and promoted with a view to their adaptation at country level. The programme also supports research to develop now tools and innovative approaches for slowing the spread of HIV and advocates for improving the quality of life of people living with HIV/AIDS. Examples are vaccine development, vaginal microbicides for women, practical approaches to reducing mother-to-child transmission of HIV, and better ways of preventing and treating the common opportunistic infections in HIV-infected individuals. Structure & staffing UNAIDS has adopted a flat organizational structure, with as few layers of management as possible. The programme consists of four departments: Policy, Strategy and Research; Country Planning and Programme Development; External Relations; and Programme Support. A total of 175 posts have been budgeted. The New York and Geneva offices currently comprise 49 professionals and 33 support staff. At country level there are 42 Country Programme Advisers, 10 Technical Advisers, 7 intercountry team members and 8 support staff. The working culture values partnership, team work and facilitation. Funding With its modest resource base of US $ 120 million for the 1998-99 biennium, UNAIDS is not a funding agency. It is a small programme that aims to increase its impact and outreach through strategic alliances with its cosponsors and other partners. UNAIDS cosponsors fund their own HIV/AIDS country-level programmes and activities. A further US $ 20 million was sought for 1998- 1999 cosponsor activities at the global and regional levels through the UNAIDS Coordinated Appeal for Supplemental Funded Activity. Funds are received from traditional donor countries, but also from developing countries (e.g. China and Thailand) and the private sector. UNAIDS aims to increase the resources available to national AIDS programmes by supporting fund-raising activities at the national level and providing training in resource mobilization to its national partners. For more Information, please contact Anne Winter, UNAIDS, Geneva, (+41 22) 791.4577 or Lisa Jacobs. UNAIDS. Geneva: (+41 22) 79 1.3387. You may also visit the UNAIDS Home Page on the Internet for more information about the programme (http://www.unaids.org) 3 100 Relatton Jre/spisun 86 AV T6L +1122 FAX 15:34 nar 66, TO/VI 001/003 FRANCE SOCIAL US 0202 944 0251 03/00/99 wall 19:01 St. Journal 6.5.99 World-wide, 34 million people are believed to be infected with HIV. the virus that causes AIDS. Bristol-Myers Chairman Charles Heim- bold, in an interview yesterday, said Foreign Aid his company's action, while perhaps slow in coming two decades into the epidemic. is a sincere effort to get other companies to Bristol-Myers Heeds join with it or to begin similar undertak- ings of their own. The 65-year-old execu- Calls to Bolster War tive says the company acted quietly and on its own "because that's the way to get things done quickly and given the Against HIV in Africa numbers we were seeing. speed seemed to be critical." While Bristol-Myers says altruism is Plan Focuses on Training. driving its efforts, there are other factors at work. The pro- Prevention Where Virus gram will allow it to develop longer-term Is Raging Most Fiercely business interests in developing na- tions for its AIDS It Isn't Only About Altruism drugs and other therapies. And in a move By MICHAEL WALDHOLZ certain to rouse eth- staff Reporter of THE WALL STREET JOURNAL ical questions in the Drug companies are facing a dilemma U.S., Bristol-Myers when it comes to dispensing powerful new hopes to support AIDS medicines where they are needed South African stud- most: sub-Saharan Africa. home to 70% of ies involving 20,000 Charles Heimbold the world's HIV-infected population. The AIDS patients, therapies are too expensive for most pa- mostly women and children, taking drug tients, and much of the region lacks basic cocktails that in some cases consist solely medical services. of Bristol-Myers's three AIDS products: its So far. most companies have tried to antiviral drugs Videx. Zerit and hydrox- deal with the problem through limited yurea. Some of the trials will involve only drug giveaways or discounting programs. two drugs, perhaps even in intermittent But many international health officials therapy, an approach considered subopti- and AIDS activists view those efforts as mal in the U.S. If proved effective, how- grossly inadequate. Already, several gov- ever, this lower-cost therapy could be a ernments, including South Africa's. are boon in the developing world. threatening to hand over drug patents to Bristol-Myers was prodded into action local manufacturers, potentially flooding when Mr. Heimbold happened to sit next to markets with cheap copycat versions of the United Nations Secretary General Kofi industry's hugely profitable anti-AIDS Annan late last year at a dinner party. medicines. and the U.N. official urged him to do Now, Bristol-Myers Squibb Co., maker something for AIDS in Africa. of three AIDS drugs, is trying another Officials with the U.N.'s AIDS program. approach. Today it is expected to an- UNAIDS, have been pounding the doors of nounce that it will spend $100 million in U.S. and European drug companies for five southern African nations over the next several years. Led by a Lebanese-born. five years to fund extensive research Paris-trained physician named Joseph trials, train more than 200 physicians and Saba, UNAIDS staffers in early 1997 began help nongovernmental organizations bol- urging AIDS drug makers to join a pilot ster community AIDS-prevention and effort to get lower-priced medicines into treatment programs. The program won't four countries, including two in Africa: include drug discounts or handouts. Uganda and the Ivory Coast. A Drop in the Bucket? But while sympathetic to the problem. the companies were uncomfortable with The effort is designed to help provide setting a precedent for a two-tier pricing the sort of in-depth, long-term care and system one for the West and one for poor research that is common in the West. nations. Their main concerns: that activ- where the death toll from AIDS has ists in Western nations would demand plunged by two-thirds in recent years. similar discounts, and that the low-priced largely as a result of the widespread use of medicines would find their way onto the the new "cocktails" of AIDS medicines. black market and end up in the U.S. and No one, not even Bristol-Myers. with Europe. $18.3 billion in annual sales, believes Moreover. Merck & Co. argued that $100 million will come close to solving the even if it halved the price of its big-selling problem. even though the company calls protease inhibitor Crixivan, which costs the effort the largest AIDS grant ever by a about $600 a month in the U.S., few Afri- corporation. The infection rate in sub-Sa- cans could afford it or use it properly haran Africa is growing by 20% a year, and because of a lack of the necessary medical in South Africa alone the number of HIV- infrastructure. Protease inhibitors are an infected people has almost doubled to close to four million in the past two years. Please Turn to Page A8, Column I Bristol-Myers Heeds Call to Bolster AIDS Warin A rica F Continued From First Page counted its AIDS drugs by 33% to 46% under essential ingredient in the multidrug cock- The Spread of HIV in Africa the pilot program. So when Mr. Annan, the tail that must be taken several times a day, U.N. secretary general, turned to Bristol- without interruption, 10 be effective in re- 1987 1997 Myers's Mr. Heimbold and asked him to ducing virus levels in the blood. Even in the take drastic action against African AIDS, U.S., many patients have difficulty adher- top management had a fairly clear under- Ing to the complex daily regimen. Merck's standing of what was needed. concern was that if patients in the pilot That was underscored when Kenneth countries went on and off the cocktails, Weg, the company's vice chairman, and they would develop drug-resistant strains several other managers visited Botswana, of the virus that could spread throughout Africa, and even imperil countries else- Swaziland and South Africa over the win- where, including the U.S. ter, accompanied by former Congressman But from the perspective of UNAIDS's Estimated Ron Dellums, a consultant and frequent Dr. Saba, a courtly man who gave up a lu- percentage of adults go-between for American companies and crative practice to work on HIV-vaccine de- Infected with HIV African governments. velopment in Rwanda, il appeared that the "You can't help but become involved 16%-32% world drug industry was principally can when you go out and see people," says the FRANCE SOCIAL US cerned about protecting huge AIDS drug 8%-16% normally strait-laced Mr. Weg. 60, who, profits in the U.S.and Europe. 0.5%-8.0% during an interview in his plush Manhat- For months, he and Brian Elliot, a gre- tan office, becomes emotional when de- Unavailable garious Irish consultant to UNAIDS, scribing his encounters with HIV-infected Source: UNAIOS women and children in Africa. At one hos- pitched their plan to company after com- pany. Their proposal called on the compa- Creating a Marketplace pital, he says quietly, he was introduced to nies to put up just $25,000 in each pilot it had to do something. "When we look a mother and her four-year-old child, both Beyond price, it was becoming clear to country to help fund an independent body back in 20 years or so, 1 wanted us to be infected, and on the spot decided to pay for UNAIDS that much more than cheap drugs that would buy AIDS drugs at steep dis- seen as on the side of those who tried, who their future medical care. was needed. Mr. Elliot, who formerly ran a counts and closely monitor their adminis- tried to do something, even in the face of Provided with data by UNAIDS, includ- Johnson & Johnson unit's drug-marketing tration to avoid misuse and theft. insurmountable odds," Mr. Young says. ing a map illustrating the disease's rapid operations in Africa in the early 1990s, had Critics in Africa were quick to point out incursion, Mr. Weg and others at Bristol- Deep Cut come to realize that a pharmaceuticals that Glaxo Wellcome's patent on AZT was Myers say they were stunned by the mag- The unlikely duo was largely met with marketplace needed to be created. In this about to expire, and said that the company nitude of the problem. "OI the 2.9 million skepticism, with one exception: Peter forum, drug makers would compete with Young, a top executive based at Glaxo was merely motivated by a desire to sus- children who have died due to AIDS, 2.5 202 944 6257 each other for patients, help train doctors Wellcome PLC's North Carolina opera- tain sales. In Uganda, Peter Mugenyi, an million of them live in sub-Saharan and support clinics and hospitals-much as eminent AIDS physician and researcher, Africa," he says. In addition, up 10 40% of tions, whose AZT Is a mainstay in treating occurs in the U.S. and in Europe. says, "I'm glad Glaxo cut its price, but if women in Swaziland and one-third of their AIDS. Mr. Young was the first drug-indus- Even Dr. Saba had to be convinced of try official to agree to slash prices, last they didn't, we would have gone else- children are also infected. In South Africa, this necessity, however. One January where" for AZT-namely to generic-drug there are 200,000 children orphaned by the June cutting AZT's monthly cost to pa- night at an Italian restaurant in Chicago, makers. disease. tients in Uganda and the Ivory Coast by where they were attending an AIDS confer- Pharmaceuticals executives say The Bristol executives weren't always more than two-thirds to about $60 a month. ence and lobbying drug makers, tempers Glaxo's willingness to slash AZT prices in warmly embraced in southern Africa-es- The company also is providing short-term flared. The normally even-keeled Dr. Saba Africa forced several other reluctant AIDS- pecially in South Africa. In one instance, AZT dosages free to pregnant women to raised his voice in frustration and said he the South Africans bristled at the com- 19:51 block the transmission of the virus to their drug makers, including Bristol-Myers and was certain the drug companies would re- Roche Holding Ltd.'s Hoffmann-La Roche pany's suggestion to train African physi- newborns. duce their prices even more, "because it's Mr. Young understood that this wasn't unit to join the UNAIDS pilot project. cians in the U.S., under a fellowship pro- right." Mr. Elliot countered sharply, However, since the project's start last gram run by Baylor College of Medicine in a solution, but he says Glaxo Wellcome felt "Joseph, the drug makers are run by busi- summer, only 650 of the two million in- Houston, rather than in Africa; it. also did- nessmen, and they respond to the market fected Ugandans have been able to afford n't seem to make sense to teach doctors 05/09/90 and to profits. Our job is to show them it's the discounted drug cocktail. Even at $200 how to use drug regimens, methods and in their interest to lower prices and help to $400 a month for the cocktail, it wasn't equipment that wouldn't be available in build a medical infrastructure in Africa." affordable for most AIDS patients in South Africa. William Malegapuru Mr. Elliot had been hammering away at Uganda. where there is virtually no health Magkoba, director of the Medical Research this theme in dozens of meetings with insurance and the cash-starved govern- Council in South Africa, says he and other drug-company executives, including sev- ment doesn't pay for drugs. black South Africans, given the recent his- eral at Bristol-Myers, which had dis- 003/003 05/06/99 19:53 20202 944 6257 FRANCE SOCIAL US tory of apartheid, are sensitive about being dictated to by white Westerners. In the end, the two sides reached a compromise: 50 South African doctors will be trained in "What Bristol is doing is sure to be seen Texas, 50 in Africa. as a mix of good citizenship and commer- cial interest," says UNAIDS's Mr. Elliot. Naive Approach "It can't help but be seen that way." Bristol-Myers staffers also concede Allen Herman, dean of the National they were "embarrassingly" naive about School of Public Health at the Pretoria- what could be accomplished. "We thought based Medical University of Southern there'd be easy answers once we got in- Africa, readily acknowledges that Bristol- volved," says Mark Ahn, the company's Myers's effort is only a tiny plece of what's project leader, who hadn't been to Africa needed. But, paraphrasing an African until a weeks-long fact-finding trip in early proverb, he says, "How do you eat an ele- February. phant? One bite at a time." Then he adds, "Our assumption was that what people "What Bristol is doing is only a bite, but needed most were drugs; maybe we could it's a big bite." make a large drug donation," Mr. Ahn says. That was before he dropped in on a support group in Soweto for 11 HIV-in- fected mothers. The women, who survived by making. peanut butter, told him they would probably best be helped with funds to pay for more equipment rather than drugs. "These women were primarily wor- ried about how they were going to support themselves today and tomorrow, not about whether they would be alive in five or 10 vears." he says. A large chunk of Bristol-Myers's money will go to train community workers in pub- lic health, and to provide existing pro- grams like the African Red Cross "with the ability to greatly expand what they are al- ready trying to do. such as caring for the orphans," Mr. Ahn says. He adds that in recent weeks, there was a "raucous" debate inside the company over exactly how much to spend, especially since the funds will come off Bristol-My- ers's bottom line. (The company says the tax deductible grant could reduce earnings by a bit less than one cent a share in each of the five years.) Only last week, Messrs. Heimbold and Weg decided on the $100 mil- lion figure, topping lesser amounts pro- posed by Mr. Ahn and others. Patent Threat Although Bristol-Myers says there isn't any connection between its effort and re- cent drug-licensing moves in Africa, some observers tie the two together. Last year, South Africa pässed a law saying it. will li- cense local manufacturers to make the anti-AIDS medicines unless big drug com- panies voluntarily reduce prices. This so upset the U.S. pharmaceuticals industry that it lobbied Congress to place a rider in a foreign appropriations bill to temporarily cut off foreign aid to South Africa: That threat postponed the South African action. Nonetheless, later this month in Geneva, the World Health Assembly of health ministers will vote at its annual meeting on a proposal to open access to the medicines through so-called compulsory li- censing that would encourage poorer na- tions to pass laws similar to the one in South Africa. FYI Richard Socarides 08/02/99 09:01:46 AM Record Type: Record To: See the distribution list at the bottom of this message CC: Subject: NC10751: Gates to give away fortune Forwarded by Richard Socarides/WHO/EOP on 08/02/99 09:01 AM [email protected] 08/02/99 03:40:00 AM Record Type: Record To: Richard Socarides@EOP CC: Subject: NC10751: Gates to give away fortune This item is copyrighted. Do not print it without permission from the originating media operation. Do not post this item in a public online forum. Items on this mailing list that are not copyrighted will not contain this message. This free mailing list is open only to people with whom I am acquainted. It has 242 recipients. LONDON, Aug. 1 (UPI) -- Bill Gates, the richest man in the world, plans to give away his $100 billion fortune, his father told the Sunday Times of London. In an interview published today, William Gates Sr. said that after leaving more than $20 million to his son, the founder of Microsoft will give the rest of his money to the William H. Gates Foundation to wipe out deadly diseases such as AIDS and malaria. The 73-year-old father of Gates said that in the next three months, the foundation will announce a number of newly funded programs that will go a long way toward its ultimate aim of becoming the world's largest private charity. Bill Gates Jr. lives with his wife and child in a mansion on the shores of Lake Washington near Seattle. Gates and his wife Melinda have previously funded a family charity that currently has $10 billion in its coffers and ranks fifth in the league of the world's philanthropic foundations. William Gates Sr., who runs the family foundation, said one of his son's favorite books is Andrew Carnegie's `The Gospel of Wealth," in which the philanthropist wrote, "The man who dies rich dies in disgrace." Gates Sr. said his 43-year-old son and daughter-in-law have been worried about world health since their visits to South Africa and India in the mid-1990s. Gates Sr., 73, said the couple found themselves increasingly concerned about the effects of disease and poverty in developing countries. "Bill and Melinda believe that one's success is not some sort of God-given thing," he said. In May, the Gates Foundation donated more than $20 million to the International AIDS Vaccine Initiative, a group based in New York that invests money in a number of research teams looking to cure Acquired Immune Deficiency Syndrome. Some have criticized Gates Jr. for making relatively small donations to charity and has been especially scorned for making donations of Microsoft-based computers to libraries. Gates Sr. said: "My son is going to have critics all his life because of his wealth. But I'm optimistic now that we have put to rest any criticism on the basis of his not being sufficiently generous. We've pretty much drowned that out." Message Sent To: Bruce N. Reed/OPD/EOP@EOP Thomas L. Freedman/OPD/EOP@EOP Maureen T. Shea/WHO/EOP@EOP Sandra Thurman/OPD/EOP@EOP Katharine Button/WHO/EOP@EOP Global HIV/AIDS Epidemic. JAMA. 1999;281:1479] (c) ht/9w.ama-assn.org/sci-pubs/jo.ost/recent/issues/jama/jsg91001.htm Journal: JAMA The Journal of the American Medical Association Medical News & Perspectives - April 28, 1999 From the Surgeon General The Global HIV/AIDS Epidemic An enormous human tragedy is unfolding in many less-developed countries because of the spread of HIV/AIDS. Of the 33.4 million HIV-infected people around the world, there are an estimated 22.5 million in sub-Saharan Africa, 6.7 million in South and Southeast Asia, 1.4 million in Latin America, and 665,000 in the United States. Globally, more than 14 million people have died of the disease, including 2.5 million last year. In many southern African countries, HIV/AIDS has become an unprecedented emergency, with 20% to 26% of people between the ages of 15 and 49 infected. In Botswana, Kenya, Malawi, Mozambique, Namibia, Rwanda, South Africa, Zambia, and Zimbabwe, HIV/AIDS will reduce life expectancy from 64 to 47 years by 2015. The progress of decades of work immunizing children, controlling diseases, and improving nutrition is being negated by HIV/AIDS. Conditions in many parts of the world promote rapid spread of the HIV/AIDS epidemic. For example, India, with a population approaching 1 billion, has estimated that 3 million to 5 million of its people are infected, and the number of new infections will double every 14 months. Social and political issues surrounding sex, injecting drug use, and blood transfusion in many countries have created special circumstances in which the disease has been able to spread unchecked. Some less-developed countries also bear a burden of political and economic instability that makes prevention even more difficult. It was only a few years ago that epidemiologists offered projections of disease prevalence for sub-Saharan Africa that were met with disbelief. If the present warnings go unheeded, South Asia, Southeast Asia, and, perhaps, China will follow the disastrous course of sub-Saharan Africa. More than a decade of experience has taught us how to control HIV/AIDS-we know what works. Many developed countries have successfully checked the spread of the epidemic. While development of therapy and a vaccine continue, prevention must be emphasized. The basic elements of prevention include education, behavior change, voluntary testing and counseling, prevention of perinatal transmission, and political commitment. Each country must find the mix of methods appropriate to its 1 of 3 5/7/99 9:48 AM Global HIV/AIDS Epidemic JAMA. 1999;281:1479] (c) tp/9w.ama-assn.org/sci-pubs/jo..ost/recent/isues/jama/jsg91001.htm particular conditions. Education about HIV/AIDS is necessary but alone does not change the behavior of populations. Promotion of voluntary testing and counseling must complement education. Testing and counseling break the deadly silence around HIV/AIDS and empower individuals to make informed decisions and change behaviors. Breaking the silence also will begin to diffuse the stigma surrounding the disease. We have seen success with behavioral change in Uganda and Thailand, the only two less-developed countries with extensive capacity for voluntary testing and counseling. It is known that perinatal transmission of HIV can be reduced by more than 50% by using antiretroviral therapy; however, problems with access to these drugs limit their use in some countries. Transmission of HIV through breast-feeding and poor survival of orphans make the avoidance of disease via treatment for perinatal transmission more complex. We continue to work with international organizations, other governments, and pharmaceutical companies to lower costs and expand access to antiretroviral drugs. Current treatment for perinatal transmission (as well as use of antiretrovirals in general) in less-developed countries is also limited by the fact that very few people have been tested for HIV infection. Treatment of other sexually transmitted diseases (STDs) is important to control the spread of HIV. One of the reasons HIV has spread so rapidly in Africa is that so many STDs go untreated. Untreated STDs break down natural barriers that prevent transmission. Access to even basic treatment for STDs remains a problem for many less-developed countries. Perhaps most important in the global battle against HIV/AIDS is political commitment. Leaders at the national, provincial, and local levels of government must speak out about HIV/AIDS and encourage businesses and nongovernmental organizations to commit to work against the disease. I was encouraged by US Vice President Al Gore and Deputy President Thabo Mbeki of South Africa, who put the HIV/AIDS threat at the top of the international agenda at the recent meeting of the United States-South Africa Joint Commission. They set an important example for leaders in developed and less-developed countries. American medicine and public health have an important role to play in the global battle against HIV/AIDS by supporting international organizations such as the Joint United Nations Program on HIV/AIDS, the World Health Organization, and the World Bank. HIV/AIDS can be likened to the plague that decimated the population of Europe in the 14th century. While the 2 of 3 5/7/99 9:48 AM Global HIV/AIDS Epidemic. [Fulltex 8 JAMA. 1999;281:1479] (c) t/.ama-assn.org/sci-pubs/jo.ost/recent/issues/jama/jsg91001.htm modern epidemic affects people of all age groups, those of working age are at highest risk, posing potentially dire economic, social, and political consequences for the global community. Unfortunately, the world continues to devote greater attention and resources to traditional national security issues such as wars, postponing notice of an epidemic that, if left to spread unchecked, will kill more people than any of the terrible conflagrations that have so marked this century. -David Satcher, MD Surgeon General of the United States and Assistant Secretary, Department of Health and Human Services (JAMA. 1999;281:1479) Table of Contents Journals . JAMA . AMNews . JAMA Condition-Specific Sites Archives of: Internal Medicine . Dermatology . Family Medicine . Ophthalmology Neurology. General Psychiatry. Otolaryngology. Surgery Pediatrics- Facial Plastic Surgery Site Update Search Guestbook Reader Services Classified Ads Advertising Information . Post Office 1995-1999 American Medical Association. All rights reserved. 3 of 3 5/7/99 9:48 AM HIV/AIDS Leadership Meeting The White House September 7, 1999 - 10:30 a.m. Overview and scope of the problem Brief outline of the Administration's new Global AIDS Initiative Increasing U.S. Government investment - Prevention - Care and treatment - Infrastructure/capacity development - Care of orphans Building partnerships Open discussion by key stakeholders Sectors Topics - Enhancing and coordinating AIDS efforts - Incorporating AIDS into existing portfolios (AIDS as a development issue; AIDS as a business issue; AIDS as an international finance issue) - Innovative approaches and partnerships Next steps August 4, 1999 Mr. John M. Doe Address Line 1 Address Line 2 City, State 20001-Zip Dear John: I am pleased to invite you to the White House on September 7, 1999, to join me and a small group of senior representatives from the United States government, multinational institutions, foundations and the corporate sector for a meeting to explore strategies to better address the international AIDS crisis. This devastating epidemic is an assault on health and development that has few, if any, modern equals. Only 20 years ago we did not know that HIV existed. At the beginning of this decade, who among us would have thought that by 1999 AIDS would be the leading cause of death in sub-Saharan Africa and the fourth leading cause of death worldwide? In the face of this reality, the President has recently asked for a $100 million increase in funding for international HIV/AIDS programs as the cornerstone of a broad and comprehensive new international initiative to combat the epidemic. This is just a part of the international effort necessary to control the spread of HIV and to deal with the associated problems of patient care. Today 34 million people worldwide are living with HIV or AIDS. AIDS related diseases have killed 14 million men, women and children--mostly in Africa where more than 5,000 deaths are reported each day. By 2010, 40 million children will have been orphaned by HIV/AIDS. Economic development in many African countries has come to a stop and the hard won social and health advances of the last 20 years are being reversed by the new realities of the epidemic. These statistics do not begin to describe the personal tragedy for many of those living with HIV/AIDS and their families. Still there is cause for hope. Throughout the world, heads-of-state are increasingly acknowledging AIDS prevention as a public health and political priority. National HIV/AIDS control strategies have been written, and Uganda and Thailand have shown that successful national AIDS prevention programs can work. Unfortunately, a serious crisis remains and much more needs to be done. Many developing countries, overwhelmed by human and financial costs, are losing the battle with the epidemic. I am asking you to join me to help build the momentum necessary to engage all stakeholders in winning the war against HIV/AIDS. Although financial support for AIDS prevention efforts remains the most critical unmet need, this meeting is not intended to be a donors conference. Rather, we will discuss strategies and identify priorities and new partnerships for assisting countries in their HIV/AIDS control efforts. We will meet at the White House on Tuesday, September 7th. Please plan to arrive at the East Appointments Gate no later than 10:00am. To confirm your participation, please call Katy Button in my office at (202) 456-6266. I look forward to seeing you on September 7th. Sincerely yours, Hillary Rodham Clinton V. Background Information 1- AIDS in Africa is a Serious Crisis 2- Press Release on Administration Initiative 3- Backgrounder on Administration Initiative 4- Wolfensohn Letter to the President 5- USTR Paper in Intellectual Property Rights 6- "Helping the Poorest" - The Economist Editorial 7- Statement and Fact Sheet on Cologne Debt Relief Agreement 8- "Helping the Poorest" - The Economist, Jeffrey Sachs article 9- "Balms for the Poor" - The Economist 10- "Orphans of the Virus" - The Economist 11- "Drugs for AIDS in Africa" - New York Times Editorial 12- "Facing a Global AIDS Crisis" - The Washington Post 13- "A Global Disaster" - The Economist 14- "In Africa, a Deadly Silence About AIDS is Lifting" - New York Times 15- HIV/AIDS Prevalence Rates for Sub Saharan Africa AIDS in Africa is a Serious Crisis But Opportunities Exist for Helping to Save Millions of Lives AIDS in sub-Saharan Africa is shattering families and communities. In many countries in southern Africa, between 16% (South Africa) and 26% (Zimbabwe) of the adult population (15 to 49) is already HIV+. UNAIDS has declared HIV/AIDS in Africa "the worst infectious disease catastrophe since the bubonic plague." In sub-Saharan Africa, each and every day more than 11,000 additional people become HIV+. In South Africa alone, at least 1,500 people a day become HIV+, 1,000 of whom are under the age of 20. 83% of all AIDS deaths to date, nearly 12 million people, have been in sub-Saharan Africa. There are over 5,500 AIDS related funerals a day in Africa. That number will rise to 13,000 a day by 2005. By 2010, more than 40 million children worldwide will be orphaned by AIDS; 95% in sub- Saharan Africa. AIDS is wiping out decades of progress on a host of development objectives in sub- Saharan Africa. According to US Census Bureau, AIDS has already reduced life expectancy Zimbabwe from 65 to 39 years, in Uganda from 54 to 43 years, and in Zambia from 56 to 37years. In the next few years, AIDS will reduce life expectancy in South Africa by a third, from 60 to 40 years. In the coming decade, AIDS will double infant mortality (infants under the age of 1) in many sub-Saharan Africa countries and triple child mortality (children ages 1 to 5). AIDS is not only causing unfathomable human suffering it is jeopardizing the economies, the stability, and civil society of many sub-Saharan African nations. AIDS is a trade and investment issue. At the recent meeting with African trade and finance ministers, Professor Jeffrey Sachs, director of the Harvard Institute for International Development, stated that, "a frontal attack on AIDS in Africa may now be the single most important strategy for economic development." According to The Economist, a recent study in Namibia estimated that AIDS cost the country almost 8% of GNP in 1996. Another analysis predicts that Kenya's GNP will be 14.5% smaller in 2005 than it would have been without AIDS, and the per capita income will be 10% lower. A report released by the World Bank last week states: "The question is, will this pandemic destroy the developing nations' hard earned economic gains or will governments get their act together in time? Clearly time is running out." AIDS has hit professionals hard in sub-Saharan Africa, particularly civil servants, engineers, teachers, miners, and military personnel. According to one study in Kigali, Rwanda, 34% of people with post-secondary education were HIV positive, compared to 18% of those with primary education, and civil servants were more than three times more likely to be HIV positive than farmers. Increased benefits and training costs, and disruption due to sick and bereavement leave are seriously affecting both the private and public sectors. Companies like British Petroleum and Barclay Bank told us that they are now hiring two employees for every one skilled job, assuming that one will die of AIDS. AIDS is a security issue. According to the Economist, "the estimated HIV prevalence in the seven armies embroiled in the Congo range from 50% for the Angolans to 80% in Zimbabweans". Recent reports confirm that 40% of the South African military is already HIV positive. US military officials have raised this as a serious stability concern. A South African anti-crime institute has linked the growing number of children orphaned by AIDS to future increases in crime and civil unrest. Without appropriate intervention, many of the 2 million children projected to be orphaned by AIDS in South Africa will raise themselves on the streets, often turning to crime, drugs, commercial sex, and gangs for survival. This not only effects social stability but also dramatically increases their risk of HIV. Determined leadership and partnerships have made, and are continuing to make, an extraordinary difference, saving millions of lives. Uganda has been the world leader in demonstrating that even a country with limited resources and low levels of literacy could turn the tide on a burgeoning epidemic. President Museveni demonstrated bold leadership early on, making every government ministry take the problem seriously, and develop and implement its own plan for reducing stigma and transmission, and caring for those who become sick. Uganda has created an enabling environment for donors, such as the US, to be active partners in the battle against AIDS. The US has invested $46 million in HIV prevention and care in Uganda (26% of all donor AIDS funding), and as a result, HIV rates have been slashed by more than half. Through stigma reduction, education, HIV counseling and testing, treatment of STDs, and community based HIV care and support, Uganda has begun to turn the tide. Countries such as Zambia, Malawi, Uganda, and Kenya have begun to develop initiatives to respond to the growing number of children orphaned by AIDS. In the longstanding African tradition, communities are finding creative ways to support the village in its efforts to raise its children, but the growing number of orphaned children already overwhelms many of these villages. Through micro-finance programs like FINCA (Foundation for International Community Assistance), women are receiving loans, starting small businesses, and with increased household incomes, taking in children orphaned by AIDS. With support of non-governmental organizations, communities are coming together to deal with school fees, nutritional assistance, immunization and oral hydration, counseling, and the range of other needs that arise for orphaned children. These efforts are low cost strategies designed to empower women, protect children, and support extended families and communities in carrying for their own. For a small fraction of the cost of one orphanage bed an entire community of vulnerable children can receive care. The problem is that only a very small number of children receive even this modest level of support. JUL-13-1035 15.14 HIDS POLICY P.02 THE WHITE HOUSE Office of the Vice President For Immediate Release Contact: Monday, July 19, 1999 (202) 456-7035 VICE PRESIDENT GORE ANNOUNCES ADMINISTRATION WILL SEEK $100 MILLION INITIATIVE- A RECORD INCREASE- IN FUNDS TO FIGHT AIDS AROUND THE WORLD Washington, DC - Vice President Al Gore today joined Archbishop Tutu, Director of the Office of National AIDS Policy Sandra Thurman, Members of Congress, and leaders of the African-American, religious, children's, and AIDS communities to announce that the Administration will seek the largest- ever budget increase in the global battle against AIDS - a new investment of $100 million, The Vice President also unveiled a new report from the Office of National AIDS Policy that assesses the AIDS crisis in Africa and recommends this investment. In addition, the Vice President announced new efforts to encourage other public and private entities across the world to address AIDS across the world. "AIDS in Africa is the worst infectious disease catastrophe in the history of modern medicine," Vice President Gore said. "More than twenty million people are now infected and nearly 500 more become infected each hour. We hope this initiative will not only provide much-needed relief but will inspire decisive action by other countries and institutions - and bring hope to the millions of children and families trapped in this horror." Today, the Vice President: RELEASED A NEW REPORT ON THE PRESIDENTIAL MISSION ON CHILDREN ORPHANED BY AIDS IN SUB-SAHARAN AFRICA. Last December, President Clinton directed the Director of the Office of National AIDS Policy to go on a fact-finding mission to assess the problem of HIV/AIDS in Africa. Today, the Vice President is releasing the report that includes new findings and a plan of action resulting from this mission. The report finds that: AIDS in sub-Saharan Africa is one of the largest health crises in the history of the world. In the past decade, twelve million people in sub-Saharan Africa have died of AIDS -- one quarter of them children -- and each day AIDS buries another 5,500 women and children. Over the next decade, AIDS will kill more people in sub-Saharan Africa than the total number of casualties in all of the wars of the 20th century combined. By 2005, the daily death toll will reach 13,000 people per day. Millions of children will be orphaned by this epidemic. In some areas up to one-quarter of all children already live with an HIV-positive parent. In the next decade, more than forty million children in sub- Saharan Africa will lose a parent to HIV/AIDS. This epidemic has a devastating impact on many aspects of life in sub-Saharan Africa. AIDS is undermining much of the progress in development that has been made in Africa. AIDS is reducing life expectancy by more than 20 years in some countries. Many children are dropping out of school to care for dying parents undermining improvements in education, and AIDS will continue to have a. major negative impact on the economy, hitting a range of professionals, from teachers to military to business leaders and therefore undermine its current trade with other nations throughout the world. UNVEILED NEW $100 MILLION INITIATIVE TO COMBAT HIV/AIDS ACROSS THE GLOBE. The Vice President also unveiled a new initiative to double the existing efforts to prevent and treat AIDS. This initiative will be targeted to Africa in addition to other parts of the world where this epidemic is growing. It will help move forward on four critically important and interconnected fronts including: Containing the AIDS Pandemic. A new $48 million initiative will be used to implement a variety of prevention and stigma reduction strategies including: HIV education; engagement of political, religious and other leaders; voluntary counseling and testing; blood supply screening, and, interventions to reduce mother-to-child transmission (MTCT). In addition, the Department of Defense (DoD) will begin new efforts to work with African militaries to provide educational material and training on AIDS prevention. Providing Home and Community-Based Care. This $23 million investment will be used to deliver counseling, support palliative and basic medical care including treatment for sexually transmitted diseases, opportunistic infections, and tuberculosis (TB) through community-based clinics and home- based care workers and enhance training and technical assistance efforts. Caring for Children Orphaned by AIDS. This new $10 million initiative will be used to assist families, extended families, and communities in caring for their children through nutrition, education, health and counseling support, in coordination with micro-finance programs. Strengthening Prevention and Treatment by Augmenting Planning, Infrastructure, and Capacity Development. This $19 million initiative will help strengthen host country ability to plan and implement effective interventions. It will also strengthen the capacity for effective partnerships between local government and community-based organizations. Strengthen local surveillance systems to track the spread of HIV infection, AIDS, and the effects of interventions to enable the best targeting of HIV/AIDS prevention programs. This United States Government investment would be provided through AID ($55 million), HHS ($35 million) and DOD ($10 million) and will be fully offset. ENGAGING OTHER PARTNERS TO ADDRESS THIS CRISIS. Addressing the crisis of AIDS worldwide will require a broad-based commitment from public and private partners across the globe, The Vice President also unveiled a series of new initiatives to enhance efforts to address this problem including: Multi-lateral Partners Meeting to Enhance Coordination Around the World. On September 7, 1999, First Lady Hillary Rodham Clinton will convene a meeting of donors, The World Bank, UNAIDS, international foundations, CEOs and others to discuss how we can best enhance and coordinate our AIDS efforts in Africa and around the world. A United Nations Conference on Children Orphaned by AIDS. The United Nations, in conjunction with the National Black Leadership Commission on AIDS, The White House Office of National AIDS Policy, The Magic Johnson Foundation and a variety of NGOs, will organize a conference on World AIDS Day to focus attention on the growing number of children orphaned by AIDS worldwide, with a special emphasis on sub-Saharan Africa. New Partnerships with Private Sector Leaders to Address This Crisis, Such As the Religious, Business and Labor Communities. -- Given the impact of AIDS on businesses active in Africa as well as the overall economic-impact on African countries, the White House will facilitate a meeting of business leaders to encourage commitment and involvement in AIDS programs, such as workplace education, outreach to communities, and increased funding support for AIDS efforts. -- The White House will host a meeting of US and African labor leaders, co-chaired by the AFL- CIO, to build on successes in working with the Council of South African Trade Unions to address AIDS. -- The White House will also facilitate a religious summit of African, American, and other religious leaders to discuss the important role of communities of faith in the fight against AIDS. In Uganda and Senegal it is very clear that the involvement of religious communities and leaders had a dramatic impact on the ability of these two countries to reduce HIV prevalence or to maintain it at low levels over time. Joining Forces for LIFE: Leadership and Investment in Fighting an Epidemic A Global AIDS Initiative I. Increasing the US Government investment in the global battle against AIDS to begin to reflect the magnitude of this rapidly escalating pandemic. Making a difference in Africa and in other highly impacted areas requires broader political commitment, enhanced community mobilization, and, most urgently, increased resources. In 1998, spending on AIDS in Africa totaled only $165 million. Compared to the ever-escalating need and other health programs, this amount is woefully inadequate. For example, in 1998, over $500 million was spent for basic childhood immunization programs in Africa. Based on our experience in those countries that are starting to demonstrate success, such as Uganda and Senegal, UNAIDS and donors now agree that a minimum of $600 million is needed in sub- Saharan Africa per year for HIV prevention alone ($2 per adult per year). While we acknowledge the leadership role that the US plays globally and the urgent need to act, clearly an effort to combat AIDS must be driven by many actors including host countries, multi-lateral organizations, and bi- lateral donors, to be successful. In FY1999, the US Government spent $74 million in USAID prevention and care in Africa and $38 million in HHS research and surveillance/prevention. But more remains to be done in sub-Saharan Africa and in other seriously affected parts of the world. The Administration proposes to commit an additional $100 million in FY2000 to the global battle against AIDS. This initiative will enable us to move forward on four critically important and interconnected fronts including: Containing the AIDS Pandemic ($48 million) Implement a variety of prevention and stigma reduction strategies, especially for women and youth, including: HIV education, engagement of political, religious, and other leaders; voluntary counseling and testing; interventions to reduce mother-to-child transmission (MTCT); and enhance training and technical assistance efforts, including Department of Defense efforts with African militaries. Providing Home and Community-Based Care ($23 million) Deliver counseling, support, palliative and basic medical care including treatment for sexually transmitted diseases, opportunistic infections (Ols), and tuberculosis (TB) through community-based clinics and home-based care workers. Enhance training and technical assistance efforts. Caring for Children Orphaned by AIDS ($10 million) Assist families, extended families, and communities in caring for their children through nutritional assistance, education, training, health, and counseling support, in coordination with micro-finance programs. Strengthening Prevention and Treatment by Augmenting Planning, Infrastructure, and Capacity Development ($19 million) Strengthen host country ability to plan and implement effective interventions. Strengthen the capacity for effective partnerships and the ability of community based organizations to deliver essential services. Strengthen surveillance systems to track the epidemic and target HIV/AIDS programs. This US Government assistance would be provided through AID ($55 million), HHS ($35 million), and DoD ($10 million). The focus of this funding is HIV prevention, and AIDS care and treatment. In those areas, this initiative represents nearly a doubling of funding in Africa from current levels ($81 million in FY99, which excludes research). The Administration recognizes the fight against AIDS must be sustained to keep pace with this burgeoning epidemic, and is committed to a multi-year effort in this critical area. II. Building partnerships with other key stakeholders to maximize our impact on the rapidly expanding pandemic. Increasing US investment in the global battle against AIDS is critical, but is not sufficient to achieve the outcomes needed. The commitment of in- country political leaders and of various segments of civil society are key to success. Moreover, resources provided by the US Government need to help leverage, and to be coordinated with, those of other donors, the private sector, and national governments to ensure synergy and to maximize impact. Building partnerships with key stakeholders in support of effective action at the community level is our greatest hope for progress. This initiative will pursue a variety of strategic opportunities for challenging other partners to join in an enhanced effort, including: Leadership Meeting On September 7, 1999, First Lady Hillary Rodham Clinton will convene a meeting of key US officials, The World Bank, UNAIDS, as well as heads of foundations, corporate CEOs, and others to discuss how best to enhance AIDS prevention and treatment efforts in Africa and around the world. The meeting will focus not only on leveraging additional resources, but also on establishing priorities, identifying effective public/private partnerships, and identifying targets for action to combat the crisis of HIV/AIDS. African Leaders Summit We propose hosting a high-level meeting with Africa government and community leaders within the next ten months. This meeting will highlight the critical role of leadership in arresting the epidemic and will work to encourage increased leadership efforts. Topics will include the economic impact of HIV/AIDS, examination of models of success in reducing the transmission of HIV, and addressing the need for increased investment in health programs. Additional topics will include AIDS care and treatment and support for children orphaned by AIDS. UN Conference on Children Orphaned by AIDS On December 1, 1999 (World AIDS Day), the United Nations in conjunction with the National Black Leadership Commission on AIDS, The White House Office of National AIDS Policy, The Magic Johnson Foundation and a variety of NGOs, will organize a conference to focus attention on the growing number of children orphaned by AIDS worldwide. Special emphasis will be placed on assessing the needs of orphaned children in sub-Saharan Africa and the Americas. Participants will include noted experts on the priority issues identified by UNAIDS, UNICEF, and other UN agencies. Business The Department of Commerce will facilitate a meeting of business leaders active in Africa to encourage them to increase their efforts to rise to the AIDS challenge. Given the impact that AIDS is having on businesses as well as the overall economic-impact on African countries, such a meeting will seek enhanced business commitment and involvement in AIDS programs. The Commerce Department will work with American Chambers of Commerce abroad and other business organizations to publicize the successful AIDS efforts of US firms in Africa and to support others taking similar action. In addition, the Department will direct work to promote closer coordination in Africa between Commercial Service Offices, other USG agencies, the business community, and African NGOs in a united effort to promote corporate partnership in AIDS programs. Labor The Secretary of Labor will facilitate a meeting of US and African labor leaders, and will be co-chaired by the AFL-CIO. The success of the AFL-CIO and its Solidarity Center in South Africa (supported by USAID) in working with the South African Trade Union Federations to include AIDS as a key labor outreach and policy issue provides a model for similar action elsewhere. Outcomes include assisting labor organizations in educating their members and securing commitments to develop workplace-based AIDS education and prevention programs, including outreach to youth. Religious Leaders Summit The US government will facilitate a meeting of African, American, and other religious leaders to discuss the important role of communities of faith in the fight against AIDS. In Uganda and Senegal, the involvement of religious communities and leaders had a dramatic impact on the ability of these two countries to reduce HIV incidence and to maintain it at low levels over time. The outcome of such a meeting would be to increase attention to the need for involving religious communities, to mobilize these organizations and leaders in the fight against AIDS, and to identify ways to support their efforts. Diplomatic Initiatives The Department of State, NSC, and ONAP will work with US and African ambassadors to increase attention to AIDS within the diplomatic community. The NSC, the Department of State, and USAID will work with G-8 and other donors, and challenge them to match the increased investment put forward in this initiative. "Joining Forces for LIFE: Leadership and Investment in Fighting an Epidemic" is an excerpt from Report on the Presidential Mission on Children Orphaned by AIDS in sub-Saharan Africa: Findings and Plan of Action, The White House, June 19, 1999. AIDS Initiative: Qs & As For Internal Use Only & Is this initiative a response to the recent problems facing the Vice President on international patents in South Africa? A: No. The President, the Vice President and others throughout this Administration recognize the critical nature of this pandemic and is committed to helping the African people combat AIDS. This effort began on December 1, 1998 (World AIDS Day) when the President and Vice President focused attention on this issue and directed AIDS czar Sandy Thurman to lead a fact finding mission to sub-Saharan Africa and report back with recommendations. Today we are releasing a report from Director Thurman and moving forward on the Plan of Action. The Vice President has worked with President Mbeki and other African leaders to address the crisis of AIDS and worked with Director Thurman and others to assure that the Administration responded to the recommendations of Director Thurman's report. The Vice President looks forward to continuing to work to find ways to address this problem. & How is the budget amendment being paid for? A: This new proposed investment of $100 million is fully paid for. The Office of Management and Budget worked with many agencies to come up with a series of reasonable offsets, such as areas where appropriated funds are in excess of what is needed. These include: $40 million comes from unspent activities at the Department of Justice for enforcement activities against unlawful diversion of prescription drug medications. $30 million in unobligated balances from the National Institutes of Health Buildings and Facilities still available because they were not spent last year. $10 million in balances from the Agency for International Development Sustainable Development Assistance Account in appropriated funds. (IF PRESSED: Typically, in the course of a given year, due to changing conditions, a small portion of AID funding is available to be shifted from one program to another. This year, there will be a shift toward prevention and treatment in Africa.) $10 million comes from a small percentage of unobligated commodity funding in the International Assistance Programs. $10 million from the Department of Defense from sales of excess raw minerals. & Are any of these funds being taken from existing AIDS programs, Africa programs, or programs to support orphans? A: None of the funds are being shifted away from AIDS, Africa or programs which provide support to orphans. These funds are additional to what is currently being spent on both AIDS and Africa. Ö Does this initiative really double funding for prevention and treatment in Africa? A. The United States Government currently spends $81 million in prevention and treatment in Africa. This new $100 million proposed for FY2000 represents a more than doubling of our investments in this area. We also are hopeful that this level of commitment will encourage other nations to step up their efforts. We need many nations and private sector commitments to address a problem of this magnitude. Q: How much of the $100 million goes towards prevention? towards treatment? A: $48 million will primarily go towards prevention and $23 million for treatment of sexually transmitted diseases and opportunistic infections. Of the remaining dollars, $10 million will provide care for children orphaned by AIDS and $19 million will strengthen prevention and treatment by augmenting planning, infrastructure, disease surveillance and capacity development. Q: How will you determine which countries receive funding? A: Countries will be chosen based on a combination of factors. The most important factor is the receptivity of host countries to partnering. Other factors to be considered include the adult HIV prevalence rates, the potential for impact, the rate of increase in HIV, the status of ongoing programs, the political commitment of governments and the opportunity for innovation. Some of the countries which are currently under consideration are: South Africa, Nigeria, Kenya, Uganda, Mozambique, Zimbabwe, Senegal, Malawi, Zambia, Rwanda, Cambodia, and India. In addition, two regional programs (West/Southern Africa Programs) may be necessary to target migrant workers, and other trans-border issues. Q: How will the US Government accomplish the goals described with only $100 million in FY2000? A: The goals are part of a larger strategy to battle AIDS outside the U.S., primarily in Sub- Saharan Africa. Our initiative seeks to link the US comparative advantage in assisting developing countries battle AIDS with that of other bilateral and multilateral donors, as well as on the host countries themselves. The battle against AIDS can not be won by the US alone or in one year. Although US leadership is a critical component of the effort, there must be a substantial effort on the part of other donors and the African nations themselves. The goals of the initiative, developed in coordination with UNAIDS, are part of a five year strategy. The global effort of all parties must be sustained over time to address this urgent problem. & Has funding been allocated for FY2001? A: It is clear that the difficult battle against AIDS will require sustained attention from the US government, other bilateral and multilateral donors and especially from the African nations themselves for many years. Our goals, which are coordinated with the UNAIDS program goals, are five year goals. We are committed to working towards reaching these important goals. (IF PRESSED:) Today we are making a commitment for $100 million in the global battle against AIDS. We have not made any funding commitments beyond this. However, recognizing the extreme need, we anticipate future funding commitments will be part of our sustained effort. 1999-SE-005934 (TUE) 6. (COPY) NO. 4260895443 P 1 the World Bank Washington, D.C. 20433 U.S.A. JAMES D. WOLFENSOHN President May 27, 1999 The Honorable William J. Clinton The President United States of America The White House 1600 Pennsylvania Avenue Washington, D.C. 20500 Dear Mr. President: The AIDS epidemic is reversing decades of progress in improving the quality of life in developing countries. More than 33 million men, women, and children are infected with HIV worldwide, and more than 90 percent of those infected live in developing countries-two-thirds in Sub-Saharan Africa. In the hardest-hit African countries, life expectancy is now 10-20 years shorter than it would have been without AIDS. Meanwhile 16,000 more people worldwide become infected each day. AIDS has therefore become a core development issue, and confronting the AIDS epidemic in developing countries has become critical to all our efforts for poverty reduction, growth, and improved quality of life. I welcome the strong concern G8 leaders have shown at past meetings, but I believe we now have to move together to a new level of action, on three fronts: First, we must reinforce political commitment and active leadership in preventing HIV/AIDS. There is no cure for AIDS and no vaccine, but there are educational and behavioral interventions that work now to curb its spread. Half of the population of developing countries-3.5 billion people-live in countries or areas where there is still time to prevent an epidemic. Top-level, visible political leadership can make a critical difference in bringing AIDS to the top of the social and political agenda. Second, we must urgently find low-cost, effective therapies that are within the reach of developing countries-for example to prevent mother-child transmission and to fight AIDS-related infections like TB-and strengthen health systems to deal with the increased demand for health care. This is particularly acute in Sub-Saharan Africa, where the largest number of AIDS patients live, health systems are weak, and the ability to pay is very low. FROM WORLD BANK FRMRP 202 522 2515 (TUE) 6. 1'99 :14/ST. 12:13/NO. 4260895443 P 2 -2- Third, we need to recognize that there is an emerging set of global health issues for which we need new approaches and instruments: accelerating the development of an HIV/AIDS vaccine that is affordable and effective in developing countries is a crucial instance. An AIDS vaccine for low-income countries is an international public good which is not likely to happen without innovative international public action. Private industry must play the critical role in developing and marketing a vaccine, but the private sector currently does not have the incentives to develop an AIDS vaccine for the strains of the virus and the health system capabilities of developing countries. There is growing consensus on the need for global partnership to ensure that AIDS vaccine development will move swiftly-but it will take a number of years, and much longer unless we act now. The Bank is already hard at work on this through a special task force charged with developing new partnerships and financing instruments which bring the private and public sectors worldwide together to speed the advent of an AIDS vaccine. In this, we are working closely with UNAIDS, WHO, the International AIDS Vaccine Initiative, and other international partners. And we are starting a major program to push much greater deployment of existing vaccines, which will be good for poor people's health now, and will also encourage industry to bring new vaccines onstream. The World Bank has lent more than US$765 million since 1986 to help developing countries deal with the AIDS epidemic, and in recent years has been lending about $1.6 billion annually for programs to strengthen health systems. But this is not enough. We are developing a new initiative of intensified action against AIDS in Africa, and I am determined that we will dramatically increase our response to this global epidemic. On all these fronts, we will work closely with our partner institutions of the UNAIDS coalition. It is time to take collective action on the G8 communiqués from Denver and Birmingham to spur the development of an AIDS vaccine, and perhaps to link this effort to other global health challenges, such as the need for new therapies and a vaccine for malaria. The international community, including the developing countries, urgently needs to elaborate a global strategy for advancing this effort, an understanding of what different actors are already doing, and where there are gaps that need to be filled. The World Bank is ready to play its part in bringing it to fruition. We will warmly welcome your support and ideas, and your commitment to urgent international action. in with Sincerely yours, /in James D. Wolfensohn cc: Hon. Robert Rubin, Secretary of the Treasury Attachment FROM WORLD BANK FRMRP 202 522 2515 (TUE) 6. 1'99 12:14/ST. 12:13/NO. 4260895443 P 3 Global Overview of the HIV/AIDS Epidemic HIV/AIDS is now the number one overall cause of death in Africa, and has moved up to fourth place among all causes of death worldwide, according to the latest annual World Health Report. An estimated 33.4 million people are living with HIV/AIDS worldwide and almost 14 million people already have died of AIDS (1998). 16,000 individuals are newly infected with HIV each day. Greater than 8.2 million children have been orphaned by HIV/AIDS. This figure may increase to 40 million HIV/AIDS orphans by 2010. Of all global regions, Sub-Saharan Africa has been hardest hit by the epidemic. The 21 countries possessing the highest HIV/AIDS prevalence rates in the world are all in this region. Two-thirds (22.5 million) of all those living with HIV/AIDS globally are from Sub-Saharan Africa The Asian HIV/AIDS epidemic is building momentum, with South and Southeast Asia experiencing the most dramatic increases in HIV infection. About 6.7 million people are presently living with HIV/AIDS in South and Southeast Asia. There is also a rapid rise in the epidemic in Eastern Europe and Central Asia. HIV/AIDS infection rates have increased six-fold between 1990-1997. Over 1.7 million people are living with HIV/AIDS in Latin America and the Caribbean. North Africa and the Middle East still possess relatively low epidemic levels, although much is still unknown about the status of the HIV/AIDS epidemic in this region. Number of Adults and Children Living with HIV/AIDS, 1998 FROM WORLD BANK FRMRP 202 522 2515 Eastern Europe and Central Asia North America Western Europe mm <<<<<<<<<< *********** 270,000 ******** 550,000 890,000 Eastern Asia, South Asia and the Pacific North Africa and the Middle East Caribbean IIII MMU 210,000 330,000 Sub Saharan Africa Latin America ********** mmmm 7,260,000 YYYYYY 1,400,000 Australia & New Zealand 12,000 (TUE) 6. 1'99 12:15/ST. 12:13/NO. 4260895443 P 4 mmmm 22,500,000 1 = 50,000 persons living with HIV/AIDS August 31, 1999 SENSITIVE For U.S. Government Use Only South Africa Intellectual Property Rights ISSUE: The SAG has undertaken to extend adequate and affordable healthcare to all South Africans. The USG supports this goal. In 1997, the South African National Assembly amended prior legislation in an attempt to ensure the supply of affordable medicines. The effect was to grant the Health Minister broad, ill-defined powers to abrogate the patent rights of pharmaceuticals companies. The pharmaceutical industry and their Congressional advocates have urged the USG to pressure the South African Government (SAG) through use of U.S. trade laws and diplomatic channels into repealing or amending the Medicines Act. At the same time, a coalition of South African and foreign pharmaceutical companies is challenging the legislation as unconstitutional in South African courts while also trying to negotiate a compromise directly with the SAG. Recently, a coalition of consumer and AIDS activists has been pressuring the USG especially the Vice President to stop pursuing the issue with South Africa in view of its HIV/AIDS epidemic. In our efforts to resolve this issue, we have recognized that the HIV/AIDS crisis in South Africa is a special situation that may require special measures. Thus, we informed the SAG and stated publicly that while we do not believe that compromising intellectual property rights is the solution to the greater problem, contrary to our general policy, we will raise no objection to compulsory licensing or parallel importing of pharmaceuticals (described below) on the part of South Africa, as long as it is done in a way that complies with the SAG's international trade obligations under the World Trade Organization Agreement on the Trade-Related Aspects of Intellectual Property Rights (TRIPS). BACKGROUND: Actions by the Administration Under the Special 301 provisions of the Trade Act of 1974, the Office of the U.S. Trade Representative is required annually to identify foreign countries that deny adequate and effective protection of intellectual property rights and to issue a public report to this effect at the end of each April. South Africa was named to the Special 301 "Watch List" (the report's lowest category) in 1998 over concern about the authority granted the Minister of Health to abrogate patent rights as well as other intellectual property issues. During this year's Special 301 review, U.S. industry recommended we designate South Africa as a "Priority Foreign Country" (the report's highest category), which could have resulted in trade sanctions. We chose not to do so, however, because we had already developed a framework to resolve our differences. As a result, South Africa was maintained on the Watch List. The framework the Administration proposed for the resolution of our differences with South Africa was through the Binational Commission, chaired by Vice President Gore and then deputy President Mbeki. The intent of the proposal was to bring together an experts group including all relevant decision makers - trade, health, and intellectual property - to reach a mutual goal of bringing better healthcare to the people of South Africa while assuring effective and adequate protection of intellectual property. Discussions have continued since the framework's acceptance. A number of South African officials have recently stated that the Medicines Act will only be used to compulsory license and parallel import pharmaceutical in a manner consistent with South Africa's international trade obligations. We are now working to obtain satisfactory assurances that the Medicines Act will be implemented in this manner so that this issue can be removed from our bilateral agenda. U.S. industry has expressed concern that any government-to-government settlement at this time could undermine their efforts to negotiate a settlement with the new government. Congress In the closing days of last year's budget process, Congressman Frelinghuysen of New Jersey inserted into the foreign aid bill a provision that blocked U.S. aid to the central Government of South Africa until the State Department provided a report explaining the Administration's efforts to obtain the repeal of the Medicines Act. Dissatisfied with State's first report, Congress asked for a revised report. The final report contains language that portrays U.S. efforts as being more aggressive. Congressional critics of the Administration's approach and consumer and AIDS activists have now seized on this report, as well as USTR's Special 301 report, as evidence of the Administration's heavy-handedness on the issue. On June 25, in a response to a letter from the Chairman of the Congressional Black Caucus, the Vice President responded stating that he supports "South Africa's efforts to enhance health care for its people -- including efforts to engage in compulsory licensing and parallel importing of pharmaceuticals -- so long as they are done in a way consistent with international agreements." On July 21, the Office of the United States Trade Representative testified before the House Committee on Government Reform's Subcommittee on Criminal Justice, Drug Policy and Human Resources chaired by Congressman Mica. In that testimony, USTR stated that, contrary to our general approach, we will raise no objection to compulsory licensing or parallel importing of pharmaceuticals on the part of South Africa, as long as it is done in a way that complies with TRIPS. U.S. Policy The Administration's approach to patent protection for pharmaceuticals is to ensure that the necessary incentives are provided to promote rapid innovation of new drug therapies and to safeguard the protection of the medicines that now exist. We generally do not support policies that allow for the parallel importation or compulsory licensing of pharmaceuticals because such practices compromise intellectual property rights and raise concerns about the safety and efficacy of imported drugs. Under U.S. law, compulsory licensing and parallel importing of pharmaceuticals is generally prohibited. However, the TRIPS Agreement does allow for these practices under certain conditions. We will not object to South Africa's efforts to compulsory license and parallel import pharmaceuticals, but want South Africa to abide by the TRIPS Agreement. Our policy approach has been responsive to both sides in this debate. On the one hand we seek to ensure that South Africa honors its international obligations with respect to intellectual property but on the other hand are demonstrating flexibility in the application of U.S. trade policy to address concerns about South Africa's HIV/AIDS crisis. Compulsory Licensing In this situation we are concerned that the South African Government would grant a compulsory license to one or more domestic manufacturer(s) for the purpose of allowing it (or them) to produce a patented drug for sale in the domestic market without the consent of the patent holder. TRIPS imposes a number of disciplines on compulsory licensing including, for example: the requirement that authorization of such use shall be considered on a case-by-case basis; such use shall be authorized predominantly for the supply of the domestic market; the right holder shall be paid adequate remuneration; and such use may only be permitted if, prior to such use, the proposed user has made efforts to obtain authorization from the right holder on reasonable commercial terms and such efforts have not been successful within a reasonable period of time. The last requirement (but not the others) may be waived in a national emergency. However, none of these conditions are included in the Medicines Act. Parallel Imports Parallel imports of pharmaceuticals are pharmaceuticals that are produced by, or with the authorization of, the patent holder and intended for sale in one market, for example Kenya, but that are diverted from the designated market, away from authorized distribution channels, and imported into another market, such as South Africa, without the authorization of the patent holder. The diversion occurs in many instances because the drugs are offered for sale in the intended market at a lower price than the market to which they are diverted. It is difficult to ensure the safety and efficacy of drugs that are parallel imported because they were not handled by authorized distributors. Thus, parallel importing of pharmaceuticals is generally prohibited in the United States and the European Union as well as Kenya. The Bernard Economist AUGUST 1999 Editorial Helping the poorest O NE world, two fates. Of children who die ny spends millions to develop a vaccine, it before their fifth birthday, 98% are in the wants an economic return. developing world. Of people who are HIV The machinery that might guarantee such positive, some 95% are in poor countries. Of a return is now taking shape. The World Bank, the millions who die prematurely of tuber- the World Health Organisation and other do- culosis, malaria, measles, tetanus and whoop- gooding bodies have formed alliances with ing cough, all but a few thousand live in the the pharmaceutical industry to promote re- poor world. Indeed, tuberculosis alone kills search on affordable drugs for neglected trop- more people each year than lung cancer, the ical ailments. Legislation under consideration most prevalent cancer and the terror of the in the American Congress and to be proposed West. The gap is widening between rich and by the European Commission would also poor countries, especially between the very give a helping hand. All this talk still needs to richest and the very poorest. Although that be backed by money, though. Others need to has happened for a century or more, the con- emulate Bill Gates's medical philanthropy. tinued early deaths of the poor and their chil- Important though such initiatives are, dren are a reproach to us all. What is to be done to save those they are not enough to heal the poor. The remarkable fall in millions of young lives? mortality. rates in Europe and North America a century ago The good news is that there is some new thinking about owed little to drugs and almost everything to improved nutri- ways to respond to this challenge. Aid agencies and drug com- tion and better public health arrangements: reliable water panies are talking to each other in more constructive ways supplies, safe drains, regular rubbish collection. Yet one in six than they once did. For donor countries, this is not mere altru- of the world's people lack safe drinking water; most of the gi- ism: as international travel grows, rich-world governments ac- ant cities of Africa and Asia have no sewerage system; and quire a direct interest in halting diseases such as tuberculosis, rubbish collection is so disorganised that between a third and which may otherwise infect their own citizens. But affordable half of their garbage lies uncollected. The main answers lie in drugs are only part of the cure. Developing-country govern- making local government more efficient and more account- ments can do more to improve the health of their people than able. Another is money-although appropriate technology simply getting hold of western money and ingenuity. can cut costs. It is quicker to help the poor by ensuring that the Part of the new thinking lies in the application of econom- water sellers on whom they rely have access to safe water ics to what has too often been a purely emotional pitch for than by struggling to install expensive piped supplies to the aid. Since it published an influential report on health in 1993, home; and wiser to arrange for septic tanks to be emptied the World Bank has consistently advanced the argument that promptly than to build water-borne sewerage systems. unhealthy countries are condemned to slow growth. The idea that ill health reinforces poverty is less familiar than the view Education for health that poverty causes ill health, but equally true. However, one With some of the diseases that kill the poor, the surest answer of the main virtues of the World Bank's argument is that it al- is to change habits. No single change would save more lives lows multinational aid donors to talk straight to developing- than if people routinely washed their hands before touching country finance ministers, who typically have more clout in food. They need, too, to filter what they drink, to feed babies the allocation of resources than do their colleagues in the hygienically, to use mosquito nets, to avoid drunken driving- health ministry. and to practise safe sex. One success story is sex education in Now, economists are tackling-or struggling with-anoth- Senegal: along with condom distribution and prompt treat- er aspect of the health of the poor: their lack of access to ment of other sexually transmitted diseases, this has helped to drugs. Jeffrey Sachs, a Harvard economist, has drawn atten- keep HIV infection rates in Dakar below 2%, compared with tion to the scale of the problem: poor countries cannot afford 20% in Kenya's Nairobi. expensive medicines, and drug companies naturally tend to Spreading such messages needs government enthusiasm. focus their research on finding cures for the ills of the rich (see But education ministers may not think it their job to teach pages 17-20 and 63) rather than the afflictions of the poor. personal hygiene, while politicians may prefer building hospi- Americans and Europeans rarely suffer from schistosomiasis, tals to preaching the virtues of hand-washing. In fact, good which afflicts 200m people worldwide, or lymphatic filariasis, health care also entails reorganising national systems so that which makes life miserable for another 120m. So the market is they concentrate on primary care for the poor, rather than said to be too small to attract research. Gone are the days five-star clinics for those, like the president and his cronies, when Jonas Salk refused to patent polio vaccine, saying that to who ought to pay for their own care. do so would be "like patenting the sun". When a drug compa- Even drug-buying could be done more effectively. Poor- THE ECONOMIST AUGUST 14TH 1999 11 LEADERS country governments need to make existing cheap medicines, drugs in Kenya was recently withdrawn by donors exasperat- such as oral rehydration salts and childhood vaccines, more ed by corruption, inertia and political chicanery. And there's available. They also need to care better for those drugs they the rub. As Professor Sachs says in his article, getting good get: all too often part of the consignment ends up on the black government is not the whole answer. But of all the ills that kill market or spoiled by bad storage. Foreign aid for malarial the poor, none is as lethal as bad government. THE WHITE HOUSE Office of the Press Secretary (Cologne, Germany) For Immediate Release June 18, 1999 STATEMENT BY THE PRESIDENT The G-7 agreement we reached today is an historic step to help the world's poorest nations achieve sustained growth and independence while targeting new resources for poverty reduction, education and combatting AIDS. It represents a sound, humane effort to promote widely shared prosperity in the new milennium. 30-30-30 Bernast THE WHITE HOUSE Office of the Press Secretary (Cologne, Germany) For Immediate Release June 18, 1999 FACT SHEET The Cologne Debt Initiative The G-7 leaders have endorsed a new Initiative to enable Heavily Indebted Poor Countries (HIPCs) to receive deeper, broader and faster debt relief in return for firm commitments to channel the benefits into improving the lives of all their people. The HIPC Initiative was created in 1996 to provide deeper multilateral debt reduction for poor countries with unsustainable debt burdens. New focus on poverty: The Cologne Initiative calls on the International Financial Institutions to develop a new framework for linking debt relief with poverty reduction that centers around better targeting of budgetary resources for priority social expenditures, for health, child survival, AIDS prevention, education, greater transparency in government budgeting, and much wider consultation with civil society in the development and implementation of economic programs. Substantially deeper relief: Together with earlier debt relief commitments, the Cologne Initiative provides for reduction of up to 70 percent of the total debts for these countries, (reducing the stock) from about $127 billion today to as low as $37 billion with the cancellation of official development assistance (ODA) debt by G-7 and other bilateral creditors. In today's dollars (net present value -- NPV terms), this would more than triple the amount of relief to be provided from $13 billion under the current HIPC framework to as much as $50 billion. This would be accomplished by reducing the HIPC program target ratios for the NPV of outstanding debt to 150 percent of exports, and 250 percent of government revenues, with fiscal thresholds of 30 percent exports to GDP and 15 percent revenues to GDP, and by providing full cancellation of ODA debts. Faster relief: Relief will be available significantly faster than under the current framework by providing early cash flow relief ("Interim Relief") and allowing earlier stock reduction. 2 Broader participation: The number of countries expected to qualify for HIPC relief would rise from 26 to 33, meaning that more than 430 million people could ultimately be affected. Releasing resources for priority needs: For the average HIPC country, the share of scarce government revenue devoted to debt service could fall by 10 percentage points to a ratio for debt service to revenues of well below 20 percent and close to 10 percent in some cases. This is equivalent to a reduction in actual payments of about 25 percent. Mozambique's debt will be reduced by some $3.5 billion ($1.7 billion in NPV terms), for example, which could cut in half the share of government revenues allocated to external debt service from over 30 percent to about 15 percent in 1999 and free about $30 million in budgetary resources each year. These savings are equivalent to over half the health budget in 1999 in a country where children are 3 times more likely to die before the age of five than they are to go to secondary school. In proposing this Initiative on March 16, President Clinton stated that "Our goal is to ensure that no country committed to fundamental reform is left with a debt burden that keeps it from meeting its people's basic human needs and spurring growth. We should provide extraordinary relief for countries making extraordinary efforts to build working economies." On June 16, the President pledged "to work to find the resources so we can do our part and contribute our share toward an expanded trust fund for debt relief." SACHS ON DEVELOPMENT Sach's Helping the world's poorest gious than any defaults by impoverished HIPCS. The broader American neglect of the UN agencies that assist impoverished coun- tries in public health, science, agriculture and the environment must surely rank as anoth- er amazingly misguided aspect of current American development policies. The conditions in many HIPCS are wors- Jeffrey Sachs, a top academic economist, argues that rich countries must ening dramatically, even as global science mobilise global science and technology to address the specific problems which and technology create new surges of wealth help to keep poor countries poor and well-being in the richer countries. The problem is that, for myriad reasons, the tech- I are nearly invisible. Seven hundred mil- OUR Gilded Age, the poorest of the poor nological gains in wealthy countries do not BY INVITATION readily diffuse to the poorest ones. Some bar- lion people live in the 42 so-called Highly In- riers are political and economic. New tech- debted Poor Countries (HIPCS), where a Jeffrey Sachs is direc- nologies will not take hold in poor societies if combination of extreme poverty and finan- tor of the Centre for investors fear for their property rights, or cial insolvency marks them for a special International Devel- even for their lives, in corrupt or conflict-rid- kind of despair and economic isolation. opment and professor den societies. The Economist's response to They escape our notice almost entirely, un- of international trade the Cologne Summit ("Helping the Third less war or an exotic disease breaks out, or yet at Harvard University. A prolific World", June 26th) is right to stress that aid another programme with the International writer, he has also advised the without policy reform is easily wasted. But Monetary Fund (IMF) is signed. The Cologne governments of many develop- the barriers to development are often more Summit of the G8 in June was a welcome ex- ing and East European countries. subtle than the current emphasis on "good ception to this neglect. The summiteers ac- governance" in debtor countries suggests. knowledged the plight of these countries, of- Research and development of new tech- fered further debt relief and stressed the and World Bank to be more sensitive to so- nologies are overwhelmingly directed at need for a greater emphasis by the interna- cial conditions is merely an indicative nod. rich-country problems. To the extent that the tional community on social programmes to A much more important challenge, as poor face distinctive challenges, science and help alleviate human suffering. yet mainly unrecognised, is that of mobilis- technology must be directed purposefully The G8 proposals should be seen as a be- ing global science and technology to address towards them. In today's global set-up, that ginning: inadequate to the problem, but at the crises of public health, agricultural pro- rarely happens. Advances in science and least a good-faith prod to something more ductivity, environmental degradation and technology not only lie at the core of long- useful. We urgently need new creativity and demographic stress confronting these coun- term economic growth, but flourish on an in- a new partnership between rich and poor if tries. In part this will require that the wealthy tricate mix of social institutions-public and these 700m people (projected to rise to 1.5 bil- governments enable the grossly under- private, national and international. lion by 2030), as well as the extremely poor in financed and underempowered United Na- Currently, the international system fails other parts of the world (especially South tions institutions to become vibrant and ac- to meet the scientific and technological Asia), are to enjoy a chance for human bet- tive partners of human development. The needs of the world's poorest. Even when the terment. Even outright debt forgiveness, far failure of the United States to pay its UN dues right institutions exist-say, the World beyond the G8's stingy offer, is only a step in is surely the world's most significant default Health Organisation to deal with pressing the right direction. Even the call to the IMF on international obligations, far more egre- public health disasters facing the poorest countries-they are generally starved for funds, authority and even access to the key negotiations between poor-country govern- ments and the Fund at which important de- velopment strategies get hammered out. The ecology of underdevelopment If it were true that the poor were just like the rich but with less money, the global situation would be vastly easier than it is. As it hap- pens, the poor live in different ecological zones, face different health conditions and must overcome agronomic limitations that are very different from those of rich coun- tries. Those differences, indeed, are often a fundamental cause of persisting poverty. Let us compare the 30 highest-income countries in the world with the 42 HIPCS (see table on next page). The rich countries over- Poverty and its ills: better remedies required whelmingly lie in the world's temperate THE ECONOMIST AUGUST 14TH 17 For fast relief from malaria for my family rely on NIVAQUINE zones. Not every country in those bands is the foundation of modern science. Global technology of significance that was not nur- rich, but a good rule of thumb is that temper- capitalism is, of course, a set of social institu- tured through public as well as private care. ate-zone economies are either rich, formerly tions-of property rights, legal and political If technologies easily crossed the ecolog- socialist (and hence currently poor), or geo- systems, international agreements, transna- ical divide, the implications would be less graphically isolated (such as Afghanistan tional corporations, educational establish- dramatic than they are. Some technologies, and Mongolia). Around 93% of the com- ments, and public and private research insti- certainly those involving the computer and bined population of the 30 highest-income tutions-but the prosperity that results from other ways of managing information, do in- countries lives in temperate and snow zones. these institutions has its roots in the develop- deed cross over, and give great hopes of spur- The HIPCS, by contrast, include 39 tropical or ment and applications of new science-based ring technological capacity in the poorest desert societies. There are only three in a sub- technologies. In the past 50 years, these have countries. Others-especially in the life sci- stantially temperate climate, and those three included technologies built on solid-state ences but also in the use of energy, building are landlocked and therefore geographically physics, which gave rise to the information- techniques, new materials and the like-are isolated (Laos, Malawi and Zambia). technology revolution, and on genetics, prone to "ecological specificity". The result is Not only life but also death differs be- which have fostered breakthroughs in a profound imbalance in the global produc- tween temperate and tropical zones. Indi- health and agricultural productivity. tion of knowledge: probably the most pow- viduals in temperate zones almost every- erful engine of divergence in global well-- where enjoy a life expectancy of 70 years or Science at the ecological divide being between the rich and the poor. more. In the tropics, however, life expectan- In this context, it is worth noting that the in- Consider malaria. The disease kills more cy is generally much shorter. One big reason equalities of income across the globe are ac- than im people a year, and perhaps as many is that populations are burdened by diseases tually exceeded by the inequalities of scien- as 2.5m. The disease is so heavily concentrat- such as malaria, hookworm, sleeping sick- tific output and technological innovation. ed in the poorest tropical countries, and ness and schistosomiasis, whose transmis- The chart below shows the remarkable dom- overwhelmingly in sub-Saharan Africa, that sion generally depends on a warm climate. inance of rich countries in scientific publica- nobody even bothers to keep an accurate (Winter may be the greatest public-health in- tions and, even more notably, in patents fil- count of clinical cases or deaths. Those who tervention in the world.) Life expectancy in ed in Europe and the United States. remember that richer places such as Spain, the HIPCS averages just 51 years, reflecting the The role of the developing world in one Italy, Greece and the southern United States interacting effects of tropical disease and sense is much greater than the chart indi- once harboured the disease may be misled poverty. The economic evidence strongly cates. Many of the scientific and technologi- into thinking that the problem is one of so- suggests that short life expectancy is not just cal breakthroughs are made by poor-coun- cial institutions to control its transmission. In a result of poverty, but is also a powerful try scientists working in rich-country labora- fact, the sporadic transmission of malaria in cause of impoverishment. tories. Indian and Chinese engineers ac- the sub-tropical regions of the rich countries All the rich-country research on rich- count for a significant proportion of Silicon was vastly easier to control than is its chronic country ailments, such as cardiovascular Valley's workforce, for example. The basic transmission in the heart of the tropics. Trop- diseases and cancer, will not solve the prob- point, then, holds even more strongly: global ical countries are plagued by ecological con- lems of malaria. Nor will the biotechnology science is directed by the rich countries and ditions that produce hundreds of infective advances for temperate-zone crops easily for the rich-country markets, even to the ex- bites per year per person. Mosquito control transfer to the conditions of tropical agricul- tent of mobilising much of the scientific po- does not work well, if at all, in such circum- ture. To address the special conditions of the tential of the poorer countries. stances. It is in any event expensive. HIPCS, we must first understand their The imbalance of global science reflects Recent advances in biotechnology, in- unique problems, and then use our ingenui- several forces. First, of course, science follows cluding mapping the genome of the malaria ty and co-operative spirit to create new the market. This is especially true in an age parasite, point to a possible malaria vaccine. methods of overcoming them. when technological leaps require expensive One would think that this would be high on Modem society and prosperity rest on scientific equipment and well-provisioned the agendas of both the international com- research laboratories. Second, scientific ad- Different ecologies vance tends to have increasing returns to Different resources Rich HIPCs* countries scale: adding more scientists to a community Indicators of global science (42) (30) does not diminish individual marginal pro- 1995, % of world totals Advanced economies Rest of world PRPST: 1,187 18,818 ductivity but tends to increasei Therein lies 0 20 40 60 80 100 at birth/ yearst 951.5 76.9 the origin of university science departments, Population ecozones, regional agglomerations such as Silicon Val- 55.6 ley and Route 128, and mega-laboratories at GDP 0.7 3.7 leading high-technology firms including Publications 17.6 Merck, Microsoft and Monsanto. And third, and snow 12.5 92,6 Patents (EU) science requires a partnership between the 14.0 2.5 public and private sectors. Free-market ideo- Patents (US) *Highly Indebted poor countries Unweighted averages Sources: J. Sachs; UNESCO logues notwithstanding, there is scarcely one 18 THE ECONOMIST AUGUST 14TH munity and private pharmaceutical firms. It such a pledge could galvanise the world of world in which science is a rich-country pre- is not. A Wellcome Trust study a few years private-sector pharmaceutical and biotech- rogative while the poor continue to die, the ni- ago found that only around $80m a year was nology firms. Malaria vaccine research ceties of intellectual property rights are likely spent on malaria research, and only a small would suddenly become hot. Within a few to prove less compelling than social realities. fraction of that on vaccines. years, a breakthrough of profound benefit to There is no shortage of complexities The big vaccine producers, such as the poorest countries would be likely. The ahead. The world needs to reconsider the Merck, Rhône-Poulenc's Pasteur-Mérieux- costs in foreign aid would be small: a few question of property rights before patent Connaught and SmithKline Beecham, have hundred million dollars a year to tame a kill- rights allow rich-country multinationals in much of the in-house science but not the bot- er of millions of children. Such a vaccine effect to own the genetic codes of the very tom-line motivation. They strongly believe would rank among the most effective foodstuffs on which the world depends, and that there is no market in malaria. Even if public-health interventions conceivable. even the human genome itself. The world they spend the hundreds of millions, or per- And, if science did not deliver, rich countries also needs to reconsider the role of institu- haps billions, of dollars to do the R&D and would end up paying nothing at all. tions such as the World Health Organisation come up with an effective vaccine, they be- Malaria imposes a fearsome burden on and the Food and Agriculture Organisation. lieve, with reason, that their product would poor countries, the AIDS epidemic an even These UN bodies should play a vital role in just be grabbed by international agencies or weightier load. Two-thirds of the world's identifying global priorities in health and private-sector copycats. The hijackers will 33m individuals infected with the HIV virus agriculture, and also in mobilising private- argue, plausibly, that the poor deserve to are sub-Saharan Africans, according to a UN sector R&D towards globally desired goals. have the vaccine at low prices-enough to estimate in 1998, and the figure is rising. There is no escape from such public-private cover production costs but not the preceding About 95% of worldwide HIV cases are in the collaboration. It is notable, for example, that R&D expenditures. developing world. Once again, science is Monsanto, a life-sciences multinational The malaria problem reflects, in micro- stopping at the ecological divide. based in St Louis, Missouri, has a research cosm, a vast range of problems facing the Rich countries are controlling the epi- and development budget that is more than HIPCS in health, agriculture and environ- demic through novel drug treatments that twice the R&D budget of the entire world- mental management. They are profound, ac- are too expensive, by orders of magnitude, wide network of public-sector tropical re- cessible to science and utterly neglected. A for the poorest countries. Vaccine research, search institutes. Monsanto's research, of hundred IMF missions or World Bank which could provide a cost-effective meth- course, is overwhelmingly directed towards health-sector loans cannot produce a malar- od of prevention, is dramatically under- temperate-zone agriculture. ia vaccine. No individual country borrowing funded. The vaccine research that is being from the Fund or the World Bank will ever done focuses on the specific viral strains People, food and the environment have the means or incentive to produce the prevalent in the United States and Europe, Public health is one of the two distinctive cri- global public good of a malaria vaccine. The not on those which bedevil Africa and Asia. ses of the tropics. The other is the production root of the problem is a much more complex As in the case of malaria, the potential devel- of food. Poor tropical countries are already market failure: private investors and scien- opers of vaccines consider the poor-country incapable of securing an adequate level of tists doubt that malaria research will be re- market to be no market at all. The same, one nutrition, or paying for necessary food im- warded financially. Creativity is needed to should note, is true for a third worldwide ports out of their own export earnings. The bridge the huge gulfs between human needs, killer. Tuberculosis is still taking the lives of HIPC population is expected to more than scientific effort and market returns. more than 2m poor people a year and, like double by 2030. Around one-third of all chil- malaria and AIDS, would probably be sus- dren under the age of five in these countries Promise a market ceptible to a vaccine, if anyone cared to in- are malnourished and physically stunted, The following approach might work. Rich vest in the effort. with profound consequences throughout countries would make a firm pledge to pur- The poorer countries are not necessarily their lives. chase an effective malaria vaccine for Afri- sitting still as their citizenry dies of AIDS. As with malaria, poor food productivity ca's 25m newborn children each year if such South Africa is on the verge of authorising the in the tropics is not merely a problem of poor a vaccine is developed. They would even manufacture of AIDS medicines by South social organisation (for example, exploiting state, based on appropriate and clear scien- African pharmaceutical companies, despite farmers through controls on food prices). Us- tific standards, that they would guarantee a patents held by American and European ing current technologies and seed types, the minimum purchase price-say, $10 per firms. The South African government says tropics are inherently less productive in an- dose-for a vaccine that meets minimum that, if rich-country firms will not supply the nual food crops such as wheat (essentially a conditions of efficacy, and perhaps raise the drugs to the South African market at afford- temperate-zone crop), rice and maize. Most price for a better one. The recipient countries able prices (ones that are high enough to meet agriculture in the equatorial tropics is of very might also be asked to pledge a part of the marginal production costs but do not include low productivity, reflecting the fragility of cost, depending on their incomes. But noth- the patent-generated monopoly profits that most tropical soils at high temperatures ing need be spent by any government until the drug companies claim as their return for combined with heavy rainfall. High produc- the vaccine actually exists. R&D), then it will simply allow its own firms tivity in the rainforest ecozone is possible Even without a vast public-sector effort, to manufacture the drugs, patent or no. In a only in small parts of the tropics, generally THE ECONOMIST AUGUST 14TH 19 on volcanic soils (on the island of Java, in In- with disturbing frequency. technological reach. Similar efforts to merge donesia, for example). In the wet-dry tropics, The United States feels aggrieved that public and private science activities will be such as the vast savannahs of Africa, agricul- poor countries are not signing the conven- needed in agricultural biotechnology. ture is hindered by the terrible burdens of tion on climatic change. The truth is that Third, just as knowledge is becoming unpredictable and highly variable water these poor tropical countries should be call- the undisputed centrepiece of global pros- supplies. Drought and resulting famine have ing for outright compensation from America perity (and lack of it, the core of human im- killed millions of peasant families in the past and other rich countries for the climatic poverishment), the global regime on intellec- generation alone. damages that are being imposed on them. tual property rights requires a new look. The Scientific advances again offer great The global climate-change debate will be United States prevailed upon the world to hope. Biotechnology could mobilise genetic stalled until it is acknowledged in the United toughen patent codes and cut down on intel- engineering to breed hardier plants that are States and Europe that the temperate-zone lectual piracy. But now transnational corpo- more resistant to drought and less sensitive economies are likely to impose heavy bur- rations and rich-country institutions are pat- to pests. Such genetic engineering is stymied dens on the already impoverished tropics. enting everything from the human genome at every point, however. It is met with doubts to rainforest biodiversity. The poor will be in the rich countries (where people do not New hope in a new millennium ripped off unless some sense and equity are have to worry about their next meal); it re- The situation of the HIPCS has become intol- introduced into this runaway process. quires a new scientific and policy frame- erable, especially at a time when the rich Moreover, the system of intellectual work in the poor countries; and it must countries are bursting with new wealth and property rights must balance the need to somehow generate market incentives for the scientific prowess. The time has arrived for a provide incentives for innovation against big life-sciences firms to turn their research fundamental re-thinking of the strategy for the need of poor countries to get the results towards tropical foodstuffs, in co-operation co-operation between rich and poor, with of innovation. The current struggle over AIDS with tropical research centres. Calestous Ju- the avowed aim of helping the poorest of the medicines in South Africa is but an early ma, one of the world's authorities on bio- poor back on to their own feet to join the race warning shot in a much larger struggle over technology in Africa, stresses that there are for human betterment. Four steps could access to the fruits of human knowledge. The dozens, or perhaps hundreds, of underused change the shape of our global community. issue of setting global rules for the uses and foodstuffs that are well adapted to the trop- First, rich and poor need to learn to talk development of new technologies-espe- ics and could be improved through directed together. As a start, the world's democracies, cially the controversial biotechnologies- biotechnology research. Such R&D is now all rich and poor, should join in a quest for com- will again require global co-operation, not but lacking in the poorest countries. mon action. Once again the rich G8 met in the strong-arming of the few rich countries. The situation of much of the tropical 1999 without the presence of the developing Fourth, and perhaps toughest of all, we world is, in fact, deteriorating, not only be- world. This rich-country summit should be need a serious discussion about long-term fi- cause of increased population but also be- the last of its kind. A G16 for the new millen- nance for the international public goods cause of long-term trends in climate. As the nium should include old and new democra- necessary for HIPC countries to break rich countries fill the atmosphere with in- cies such as Brazil, India, South Korea, Nige- through to prosperity. The rich countries are creasing concentrations of carbon, it looks ria, Poland and South Africa. willing to talk about every aspect except ever more likely that the poor tropical coun- Second, rich and poor countries should money: money to develop new malaria, tu- tries will bear much of the resulting burden. direct their urgent attention to the mobilisa- berculosis and AIDS vaccines; money to spur Anthropogenic global warming, caused tion of science and technology for poor- biotechnology research in food-scarce re- by the growth in atmospheric carbon, may country problems. The rich countries should gions; money to help tropical countries ad- actually benefit agriculture in high-latitude understand that the IMF and World Bank are just to climate changes imposed on them by zones, such as Canada, Russia and the north- by themselves not equipped for that chal- the richer countries. The World Bank makes em United States, by extending the growing lenge. The specialised UN agencies have a mostly loans, and loans to individual coun- season and improving photosynthesis great role to play, especially if they also act as tries at that. It does not finance global public through a process known as carbon fertilisa- a bridge between the activities of advanced- goods. America has systematically squeezed tion. It is likely to lower tropical food produc- country and developing-country scientific the budgets of UN agencies, including such tivity, however, both because of increased centres. They will be able to play that role, vital ones as the World Health Organisation. heat stress on plants and because the carbon however, only after the United States pays its We will need, in the end, to put real re- fertilisation effect appears to be smaller in debts to the UN and ends its unthinking hos- sources in support of our hopes. A global tax tropical ecozones. Global warming is also tility to the UN system. on carbon-emitting fossil fuels might be the contributing to the increased severity of We will also need new and creative insti- way to begin. Even a very small tax, less than tropical climatic disturbances, such as the tutional alliances. A Millennium Vaccine that which is needed to correct humanity's "one-in-a-century" El Niño that hit the trop- Fund, which guaranteed future markets. for climate-deforming overuse of fossile fuels, ical world in 1997-98, and the "one-in-a-cen- malaria, tuberculosis and AIDS vaccines, would finance a greatly enhanced supply of tury" Hurricane Mitch that devastated Hon- would be the right place to start. The vaccine- global public goods. No better time 10 start duras and Nicaragua a year ago. Once-in-a- fund approach is administratively straight- than as the new millennium begins. century weather events seem to be arriving forward, desperately needed and within our 20 THE ECONOMIST AUGUST 14TH SCIENCE AND TECHNOLOGY pharmaceutial ket. But as Patrice Trouiller. a consultant with Médecins sans Frontières (MSF), an aid group, points out, only 11 of them were de- signed for tropical diseases. The problem is not merely one of human welfare, important though that is. Many eco- nomists, among them Jeffrey Sachs of Har- vard University (see pages 17-20), believe it is also an issue of economic development. Bet- ter access to better medicines is not the only way to improve the health of poor countries, but it is a significant one. And creating new drugs and vaccines is such a technology- intensive business that the developing world is likely to remain dependent on western pharmaceutical firms for years to come. New pills, old ills Encouraging the development of new med- icines is difficult because it requires both the push of financial incentives (to offset the risk Balms for the poor of research in largely uncharted fields) and the pull of secure funding (to ensure that there is a paying market once the drugs are ready). Recently, however, some new ideas about how to solve these problems have emerged, based on new alliances between industry and the public sector. One approach is that being taken by the Infectious diseases hinder developing countries from developing. Making new Medicines for Malaria Venture (MMV), existing drugs cheaper there would help. Making entirely new drugs would which brings together public-sector organi- help even more sations and drug companies under the um- brella of the WHO. Robert Ridley, director of P EER over the counter at a pharmacy in supermodels than charities: they won't get MMV, sees the venture as a "not-for-profit America, Europe or Japan and you see a out of bed and into work for less than $350m virtual drug company", combining public- wealth of drugs. Americans and Europeans in annual sales for any given product. This is and private-sector research through funding spend more than $220 billion a year on pre- because turning a gleam in a researcher's eye collaborative discovery and development scription medicines for everything from into a handful of useful pills is an expensive projects. Drug companies have millions of high blood pressure to low mood-a power- and time-consuming business: on average, it molecules in their chemical libraries created ful incentive for pharmaceutical companies costs $300m and takes more than a decade. for more lucrative diseases such as cancer, to keep them supplied with current reme- Between 1975 and 1997, an impressive 1,223 along with thousands of old drugs currently dies and to concoct new ones (see chart). Of new compounds were launched on the mar- used for other ailments, which could be de- course, drugs for such diseases as river blind- veloped for malaria at roughly a tenth of the ness and sleeping sickness are not routinely Overdosed cost of starting from scratch. found on western shelves since there is little Pharmaceuticals market, 1999 But finding the money to finance the re- demand for them. But walk into a dispen- $bn search is not easy. MMV aims to register one sary in, say, Cameroon, and you discover North America 8.6 new antimalarial product every five years, that such drugs are equally scarce there-not and is likely to need $30m a year to do so. The because they are not needed, but because Europe 5.3 drug companies' gifts-in-kind are worth mil- nobody can afford them. Japan 0.2 lions, but the bulk of the required money is Lack of money not only restricts access Latin America 7.2 still expected to come from public funds and to existing drugs and vaccines and means of South-East Asia, philanthropic institutions. Initial promises dispensing them; it also offers little incentive China 11.1 of $5m have enabled MMV to begin the pro- for drug companies to develop new medi- Middle East 10.4 cess of project selection, and the venture will cines for people in poor countries. Globally, Eastern Europe 9.4 be formally launched later this year. the World Health Organisation (WHO) esti- Seth Berkley, head of the International mates that more than $56 billion a year is Indian subcontinent 7.9 AIDS Vaccine Initiative (IAVI), is hoping to do spent on health research-but less than 10% Africa 3.2 something similar for AIDS vaccines. Rough- of that sum is directed toward diseases that ly $2 billion a year is spent on research into Australasia afflict 90% of the world's population. Annual 9.2 change, AIDS treatments, most of which are either As Piers Whitehead of Mercer Consult- CIS 1999-2003 6.1 too costly or too complicated for use in poor ing notes, large drug companies are more like Source: IMS HEALTH ALL countries. But IAVI estimates that only THE ECONOMIST AUGUST 14TH 1999 63 SCIENCE AND TECHNOLOGY Flying high control circadian rhythm-also lack heightened responses to cocaine even after multiple doses. In fact, "Doubletime" mut- C OCAINE, as addicts well know, has Other experiments on mice and flies have ants proved particularly resistant to the curious effects on the body. One of shown that dopamine is also involved in drug, requiring substantially higher quan- them is "reverse tolerance": rather than be- cocaine sensitisation. So the researchers tities before behaving strangely. coming accustomed to cocaine with in- put the two together and decided to see In fruit flies, a biochemical called tyra- creasing exposure (as happens with, say, whether disrupting the body's internal mine seems to be responsible for such drug alcohol), the brain becomes more sensitive. clock might also affect cocaine craving. responses, and Dr Hirsh thinks that tyra- With each hit, responses, such as fidgeting, When exposed to purified "freebase" mine regulation is the chemical link bet- are more exaggerated. This sensitisation is cocaine, fruit flies behave surprisingly like ween these two very different processes. thought to be a first step in creating an over- junkies. They twitch, gnaw and groom After a single cocaine dose, the enzyme whelming craving for the drug that eventu- themselves compulsively while wandering that makes tyramine becomes more active ally leads to addiction. about in circles. As the drug dose rises, such in normal flies. In the circadian-gene mut- In humans, studying cocaine sensitisa- erratic movements become more severe ants, however, the enzyme's activity stays tion is tricky since most governments have until the fly is paralysed and drops dead. steady after a dose of the drug, so tyramine strong views on giving drugs to the uniniti- Ordinarily, one cocaine hit is enough to levels remain low. The absence of the circa- ated, and tend to enforce them with leng- sensitise a fly. But Dr Hirsh's team found dian genes, which seem to regulate the thy prison sentences. So instead research- that mutant Drosophila lacking genes release of tyramine, prevents flies from ers have turned to creatures such as the called "Clock", "Period", "Cycle" and becoming more responsive to cocaine. fruit fly, Drosophila melanogaster, to "Doubletime"-all of which are known to Whether sky-high flies can teach scien- probe the cellular basis for co- tists much about human addic- caine craving. In this week's issue tion remains to be seen. Only of Science, biologists Jay Hirsh, about a fifth of the people who Sarah Chaney and Rozi Andretic use cocaine actually become ad- of the University of Virginia re- dicted to it: the puzzle lies in un- port that an appetite for cocaine derstanding what distinguishes seems to be connected to the the casual user from the hard- mechanisms which control circa- core addict. But if the propensity dian rhythm-the so-called to addiction is also genetically "body clock". controlled in humans, it could Fruit flies, like humans, have provide a mechanism to address an internal biological clock that the problem at the cellular level, governs their activity over a 24- by regulating tyramine or its ver- hour cycle. Ms Andretic recently tebrate equivalent. It might then found that the brain makes use of be possible to treat cocaine addic- a biochemical called dopamine tion as a disease, rather than a to regulate its circadian rhythm. Fruit flies on the rocks criminal activity. $250m is spent creating vaccines, few of as well. Another proposal is to allow compa- of 1999, introduced by Nancy Pelosi, aims to which are potentially useful for poor coun- nies that agree to develop an HIV vaccine a encourage drug makers to develop vaccines tries where about 95% of HIV infections oc- limited extension to their patents on block- for malaria, tuberculosis and HIV, which to- cur. Dr Berkley wants to make life as easy as buster drugs in their most lucrative markets. gether kill almost 8m people each year. The possible for potential vaccine developers by A different approach, being cham- legislation proposes substantial tax credits mustering expertise and money to help com- pioned by MSF, is to make a virtue of the rar- on research and development expenses, and panies negotiate regulatory hurdles and or- ity of tropical diseases in the West. Since 1983 would cost about $25m a year. ganise clinical trials in developing countries. America has offered incentives in the form But while the bill has received backing IAVI is also trying to use the tricky issue of of tax credits and marketing monopolies to from both politicians and industry execu- intellectual property to expand access to companies willing to develop drugs for "or- tives for its tax credits, it may face opposition new vaccines. Patents have long been a sore phan" diseases, which afflict fewer than to its explicit endorsement of "tiered pric- point between the companies which own 200,000 people and so offer markets too ing"-the simple idea that poor countries be them and developing countries (such as small to attract much attention from phar- charged less than rich ones for drugs. In the South Africa) which want to get their hands maceutical companies. The European Com- past, American congressmen have com- on nifty new medicines and resent having to mission is preparing similar legislation, and plained that it is "unfair" that their voters pay the premiums which patent-holders ex- Dr Trouiller of MSF is lobbying for tropical should pay 100 times more for a measles vac- pect as a reward for their innovation. IAVI diseases to be included in it. But although or- cine than, say, a mother in Bangladesh. will invest in drug companies if they prom- phan drug legislation has been a boon to Such opposition to tiered pricing alarms ise to provide their vaccines to poor coun- America's biotech companies, which can drug companies, according to Amie Batson, a tries (though not rich ones) at just above use the prospect of a market of a few million vaccine consultant with the World Bank. manufacturing cost, rather than including dollars to lure investors, that is scarcely loose Even more worrying, says Walter Vanders- the usual hefty margin. If they do not, IAVI change for large pharmaceutical firms. And missen, head of government affairs at Smith- has the right to transfer the patent to another since only big firms can manufacture drugs Kline Beecham Biologicals, is the prospect producer. IAVI has already struck a deal with in large quantities, it is crucial to engage their that rich countries might allow the import of one biotech company, Alphavax of North interest too. discounted drugs from poor countries, and Carolina, along these lines and is hoping to A bill now before Congress could do just undercut the drug industry's sales in their do business with large pharmaceutical firms that. The Lifesaving Vaccine Technology Act profitable markets. (At the moment, America 64 THE ECONOMIST AUGUST 14TH 1999 and the European Union strictly control im- ports of drugs made outside their borders.) Though many in the pharmaceutical in- dustry are impressed by these proposals, some feel that there are now too many com- peting "initiatives" and that they all fall short of inspiring novel drug development. Mr Vandersmissen considers them "interest- ing think-tank exercises". The best way to stimulate new research, he believes, is to prove that sustainable markets can be creat- ed for relatively expensive medicines al- ready on the shelf. This is the aim of a new in- ternational consortium, the Global Alliance for Vaccines and Immunisation, to be launched next year. It brings together the World Bank, the WHO, wealthy donor coun- tries, poor recipient ones, philanthropic or- ganisations and the drug industry, with the aim of improving access to existing vaccines and developing new ones. According to Geoffrey Lamb, head of "resource mobilisation" at the World Bank, one way to finance such a programme is through a global trust fund for vaccines for needy countries. But wealthy donor govern- ments are not keen to tie up large sums of money for long periods of time on uncertain odds. A more likely prospect, in Mr Lamb's view, is "contingent lending", in which do- nors promise to give money and needy countries promise to buy a vaccine if and when a useful one appears. Ultimately, says Tim Evans, director of health sciences at the Rockefeller Founda- tion, rich donor countries prefer to give their money to projects (such as drug donation and immunisation programmes) which show results in a couple of years, rather than put up with the long and uncertain slog of developing new medicines. But some donors are prepared to take a more long-term view. The biggest splash has been made by the Bill and Melinda Gates Foundation. Since last December, the foundation has given $50m for malaria vaccine development, $25m for AIDS vaccine research and $100m to the Gates Children's Vaccine Programme which aims to improve access to expensive new shots against hepatitis-B, Haemophilus in- fluenzae and rotavirus. Though such contributions are wel- comed by international health workers, they are, in Mr Evans's view, largely "catalytic"- enough to kickstart a reaction among drug developers and public health authorities, but not enough to sustain it. He would like to see a new group of donors: multinational corporations whose business in poor coun- tries depends on a healthy workforce, who would benefit from novel drugs for their old ailments. In the end, developing new medi- cines for the world's poorest will depend on appeals to both altruism and self-interest. Balancing the two may prove the toughest trick of all for the new alliances between the public and private sector. THE ECONOMIST AUGUST 14TH 1999 INTERNATIONAL AIDS orphans dren and 68% of rural orphans in Zambia do not attend any classes at all. In Ndola, unem- ployment has become the norm as the cop- per mines, mismanaged for decades, are now sacking workers by the thousand. Hun- dreds of families face eviction from mine- owned houses. In the recently expanded cemeteries around Ndola, several graves have been dug up: local thieves are so des- perate that they strip fresh corpses of the smart suits in which they are buried. State welfare payments reach less than 2% of Zambians; charitable organisations help only a tenth. Almost the entire burden of coping with the orphan problem falls on the extended family. Zambian families have adapted impressively to the crisis. According to one study, 72% of Zambian households care for one or more orphans. Zambia's old socialist regime preferred to put orphans into state institutions, but the current gov- ernment, arguing that orphanages are an ex- pensive way of making children miserable, has closed almost all of them. Orphans of the virus Most orphans are now fostered by rela- tions, who offer more love and pumpkin- leaf stew than the government ever could. But extra mouths mean less food to go round, so many fostered children are made to work for their keep. And since fostering is NDOLA, ZAMBIA informal, orphans usually enjoy fewer legal rights than other children. Formal adoptions The AIDS epidemic is leaving a horrifying number of African children require paperwork and the co-operation of without their parents sluggish bureaucrats, so they are rare: in 1996 there were only 18 in the whole of Zambia. T WO-THIRDS of the patients at the main mates of the proportion of Zambian chil- The unlucky ones receive no care at all. hospital in Ndola, in the copper-mining dren under 15 who have lost one or both par- Babies born H1V-positive in Zambia usually region of northern Zambia, are dying of AIDS. ents (usually but not always from AIDS) die within a year. Uninfected babies should Some have lost so much weight that their range from 13% to as high as 50%. Even at the be able to survive, but, if the mother dies, her arms look like broken broom handles and lowest estimate, this is a dozen times higher relations sometimes wrongly think the baby their tattoos are shrivelled and illegible. than the level in industrialised countries. too is doomed, and so do not waste scarce Their immediate wish is not for costly anti- It is not only children who are hit. Faides food delaying the inevitable. The disease has retroviral drugs, but for food. In theory, the Zulu, a grandmother from a shanty town led to a dramatic increase in the number of state-run hospital provides meals for all pa- outside Ndola, was supported by her daugh- homeless children: perhaps 90,000 live on tients, but several complain that they have ter until she and her husband both died. Zambia's streets or in the bush, scratching a not eaten all day, and beg for 100 kwacha Suddenly, Mrs Zulu had lost her only source living by recycling broken bottles or through (four American cents) for breakfast. of income and gained five new dependants. petty theft. Too poor to afford glue to dull the Poverty hastens death among AIDS suf- Despite her age (she is old enough to have no evening chill, they sniff fermented sewage. ferers. And in Zambia, as in much of Africa, idea when she was born) and frailty, she has Other African countries' statistics on the sheer number of AIDS deaths aggravates resumed the heavy task of growing vegeta- AIDS orphans are even less reliable than the poverty of those who survive. The dis- bles in her small plot and carrying them to Zambia's. But a study of 19 sub-Saharan ease in Zambia is so common that it has lost market. Hand-outs from a local charity cover countries by USAID reckoned they would its social stigma. The Zambian health minis- clothes and the $7-a-year school fees for have 40m orphans by 2010, largely because try estimates that half the country's popula- each child. She says that without the 25kg of of AIDS. According to the UN, there were 35 tion will eventually die of it. Only tycoons maize meal she is given each month, the fam- countries (all poor) where the proportion of and cabinet ministers can afford proper ily would starve. orphans doubled, tripled or quadrupled bet- treatment. The death toll is worse than any- Many are less fortunate. About half of all ween 1994 and 1997. However good the care thing Peter McDermott, who runs the Zam- Zambian children are malnourished to the of these children, it is hard to imagine robust bian office of Unicef, the UN'S agency for point of being stunted, a fifth severely so. economic growth where so many adults are children, has seen in the numerous war Lack of food hinders these children's mental dying in their productive prime, leaving the zones where he has worked. Most of those development. Lack of education retards very young and the very old to cope alone. who die are mothers or bread-winners. Esti- young brains still further: half of rural chil- 35 THE ECONOMIST AUGUST 14TH 1999 THE NEW YORK TIMES EDITORIALS/LETTERS MONDAY, AUGUST 23, 1999 Drugs for AIDS in Africa The average African nation spends less than to recover the research and development costs of $10 per person each year on health care. The mix of all their projects, even the unsuccessful ones. drugs, including the new protease inhibitors, neces- The drug companies, and the Clinton Adminis- sary to turn AIDS from a death sentence into a tration's trade negotiators, have fought the efforts chronic disease costs at least $12,000 per person of third-world countries to manufacture or import each year. That disparity virtually guarantees that cheap versions of still-patented drugs. American most of the 22 million Africans infected with the trade pressure on Thailand throughout the 1990's, AIDS virus will not get the best available treatment. for example, caused the country to put restrictions Few will even be able to afford less expensive life- on its manufacture of cheap patented drugs and ban prolonging drugs such as AZT or ddI or - far their import, which AIDS doctors say reduced the cheaper and just as crucial - medicines to fight the country's ability to fight the disease. infections that accompany AIDS. What really worry the drug industry today, Washington is now arguing with South Africa however, are the new intellectual property rules of about a new law in that country that could allow the World Trade Organization. Over Washington's South Africa to make cheap versions of still-patent- objections, poor nations won the right to make ed drugs or import them at less than the manufac- patented drugs in certain situations, especially turers want to charge. The debate is important, and when there is a "national emergency." While Wash- it has revealed the need to broaden the Administra- ington says it objects to technicalities in the new tion's policy, which has been dominated by trade South African law, the larger reason trade officials issues and the desire to protect American pharma- have pressed so hard is that the industry fears ceutical patents. Washington should stop pressuring South Africa could set precedents, within the South Africa to change the law, but even then far world's trade rules, for the manufacture of cheap more will need to be done to get lifesaving medi- drugs. Drug makers have sued in South African cines to poor Africans with AIDS. courts to block the law. While defending intellectual property is impor- tant, the narrowness of the Administration's views Part of the challenge is to increase the avail- is dismaying. Pharmaceutical companies would ability of already affordable drugs. Last month, the lose little if they found legal and controllable ways Administration announced a $100 million effort to to let poor countries - which offer scant market fight AIDS in Africa. It will buy and help countries anyway - reproduce drugs or buy them cheaply. use some cheap treatments, like medicines for In addition, some of the most important AIDS tuberculosis and other AIDS-related infections and drugs were discovered in the National Institutes of drugs to prevent mother-child transmission. Health, or with Government grants. Two examples While some pharmaceutical manufacturers, are ddI and the protease inhibitor Norvir. That most recently Bristol-Myers Squibb, are making financing may well give Washington the right to substantial donations to fight AIDS in poor coun- allow the World Health Organization to license the tries, they want to see governments or health drugs' manufacture, for sale only in poor nations in organizations bear the cost of AIDS drugs. But most case of emergency. The Administration should ex- of the newer ones are far too expensive. Many third- plore this option for all such vital medicines devel- world countries have long responded to the high oped at taxpayer expense. The desires of America's cost of patented drugs by copying them, sometimes pharmaceutical companies have been the over- for a tenth of the patented price. The pharmaceuti- whelming force driving American policy on the cal industry argues that this pirating discourages issue of drugs in poor nations. Surely the needs of 35 the search for new medicines, as patented drugs million people infected with H.I.V. worldwide should are priced high in part to allow manufacturers count for more. Princeton N. Lyman Facing a Global AIDS Crisis Washington Post vsbc noffhe toll from the HIV/AIDS epidemic is or intellectual property protection. The companies and African and other nations relatively low-cost medicine available free becoming more evident each day. Last year South African challenge is technically not under siege. This is the discovery of a or at least at cost, and the governments of close to 2 million people worldwide died aimed at AIDS medicines per se. But the relatively simple means of interrupting the Asia and Africa to launch and oversee the from the disease. The number of AIDS confrontational attitude behind these chal- transmission of HIV from an infected program. orphans is horrifying: 8.3 million children, lenges has its origins in the AIDS crisis. mother to the unborn child. At least this This is still a small step toward control- according to UNICEF. Most African countries would be unable much could be addressed now. ling this disease. Some day, a much greater Less well reported is the growing eco- to administer the complex use of AIDS Such a partnership would involve major partnership will be needed to administer a nomic impact. In Zimbabwe, companies "cocktails" even if the price were within donors, such as the United States, to cover vaccine, once it is developed. For now, report training seven workers for each job, as the death roll is so great. In Zambia, reach. But a new development has offered the administrative costs, UNICEF to en- however, pharmaceutical companies, colleges graduated 300 new teachers last the prospect of a partnership between the sure proper ministration of the medicine, which have been notoriously insensitive to year; but AIDS took the lives of 600. In the pharmaceutical companies to make this the underlying crisis when vigorously de- international community, pharmaceutical fending their patent rights (Bristol-Myers South Africa, analysts predict that the being a welcome exception), can demon- epidemic could kill up to 10 percent of the strate concern in a tangible way. mitting work force each year. AIDS will For Vice President Al Gore, dogged by drive up the payroll costs of this critical protesters over his alleged defense of the industry in South Africa by 45 percent, an pharmaceutical industries' claims against industry already racked by falling world South Africa, this would be a most appro- prices. priate initiative to lead. It would have far While the impact today is greatest in more impact than the extra $100 million Africa, the rate of spreading infection in request for HIV/AIDS he recently an- South Asia is one of the most rapid in the nounced with Archbishop Desmond Tutu, world, threatening havoc in that already as welcome as that is. volatile region within a decade. The HIV/AIDS epidemic is perhaps the Faced with this devastating epidemic, most serious source of future social and African countries have become increas- economic upheaval in large parts of the ingly frustrated with the gap between the world today. It demands initiatives far industrialized countries' ability to treat greater than anything done so far. A AIDS patients, and thus lower death rates, and their own lack of the resources to do public-private partnership as described here could be the forerunner of the kind SO. This has led to attacks on the patent rights of pharmaceutical companies, by that eventually will be needed. South Africa in particular, and challenges to these rights by others in the World The writer, a former U.S. Health Organization. ambassador to South Africa, is a Led by Zimbabwe, countries are arguing visiting fellow at the Overseas that health should take priority over trade ASSOCIATED PRESS Development Council. AIDS IN THE THIRD WORLD Bernard gand, 1999 AIDS was already devastating Africa. So far, the worst-hit areas are east and southern Africa. In Botswana, Namibia, Swaziland and Zimbabwe, between a fifth and a quarter of people aged 15-49 are af- flicted with HIV or AIDS. In Botswana, chil- dren born early in the next decade will have a life expectancy of 40; without AIDS, it would have been nearer 70. Of the 25 monitoring sites in Zimbabwe where preg- nant women are tested for HIV, only two in 1997 showed prevalence below 10%. At the remaining 23 sites, 20-50% of women were infected. About a third of these women will pass the virus on to their babies. The region's giant, South Africa, was largely protected by its isolation from the rest of the world during the apartheid years. Now it is host to one in ten of the world's new infections-more than any other coun- try. In the country's most populous prov- ince, KwaZulu-Natal, perhaps a third of sex- ually active adults are HIV-positive. Asia is the next disaster-in-waiting. Al- ready, 7m Asians are infected. India's 930m people look increasingly vulnerable. The Indian countryside, which most people imagined relatively AIDS-free, turns out not A global disaster to be. A recent study in Tamil Nadu found over 2% of rural people to be HIV-positive: 500,000 people in one of India's smallest states. Since 10% had other sexually trans- mitted diseases (STDS), the avenue for fur- PIETERMARITZBURG, HARARE, KAMPALA ther infections is clearly open. A survey of female STD patients in Poona, in Maha- The AIDS virus has infected 47m people, and shows no signs of slowing. It rashtra, found that over 90% had never had cannot be cured. Can it be curbed? sex with anyone but their husband; and yet 13.6% had HIV. China is not far behind. I N RICH countries AIDS is no longer a diarrhoeal disorders and tuberculosis. It No one knows what AIDS will do to death sentence. Expensive drugs keep now claims many more lives each year poor countries' economies, for nowhere HIV-positive patients alive and healthy, than malaria, a growing menace, and is still has the epidemic run its course. An op- perhaps indefinitely. Loud public-aware- nowhere near its peak. If India, China and timistic assessment, by Alan Whiteside of ness campaigns keep the number of in- other Asian countries do not take it seri- the University of Natal, suggests that the ef- fected Americans, Japanese and West Euro- ously, the number of infections could reach fect of AIDS on measurable GDP will be peans to relatively low levels. The sense of "a new order of magnitude", says Peter Piot, slight. Even at high prevalence, Mr White- crisis is past. head of the UN'S AIDS programme. side thinks it will slow growth by no more In developing countries, by contrast, The human immuno-deficiency virus than 0.6% a year. This is because so many the disease is spreading like nerve gas in a (HIV), which causes acquired immune defi- people in poor countries do not contribute gentle breeze. The poor cannot afford to ciency syndrome (AIDS), is thought to have much to the formal economy. To put it even spend $10,000 a year on wonder-pills. Mil- crossed from chimpanzees to humans in more crudely, where there is a huge over- lions of Africans are dying. In the longer the late 1940s or early 1950s in Congo. It supply of unskilled labour, the dead can term, even greater numbers of Asians are at took several years for the virus to break out easily be replaced. Some people argue that risk. For many poor countries, there is no of Congo's dense and sparsely populated those who survive the epidemic will benefit greater or more immediate threat to public jungles but, once it did, it marched with from a tighter job market. After the Black health and economic growth. Yet few po- rebel armies through the continent's nu- Death killed a third of the population of litical leaders treat it as a priority. merous war zones, rode with truckers from medieval Europe, labour scarcity forced Since HIV was first identified in the one rest-stop brothel to the next, and even- landowners to pay their workers better. 1970S, over 47m people have been infected, tually flew, perhaps with an air steward, to Other researchers are more pessimistic. of whom 14m have died. Last year saw the America, where it was discovered in the AIDS takes longer to kill than did the biggest annual death toll yet: 2.5m. The dis- early 1980s. As American homosexuals and plague, so the cost of caring for the sick will ease now ranks fourth among the world's drug injectors started to wake up to the be more crippling. Modern governments, big killers, after respiratory infections, dangers of bath-houses and needle-sharing, unlike medieval ones, tax the healthy to 42 THE ECONOMIST JANUARY 2ND 1999 AIDS IN THE THIRD WORLD help look after the ailing, so the burden will ous, AIDS could break budgets and hobble War. Refugees, whether from genocide in fall on everyone. And AIDS, because it is sex- the provision of services. In South Africa, Rwanda or state persecution in Myanmar, ually transmitted, tends to hit the most en- an estimated 15% of civil servants are HIV- spread HIV as they flee. Soldiers, with their ergetic and productive members of society. positive, but government departments regular pay and disdain for risk, are more A recent study in Namibia estimated that have made little effort to plan for the com- likely than civilians to contract HIV from DS cost the country almost 8% of GNP in ing surge in sickness. Education, too, will prostitutes. When they go to war, they infect 6. Another analysis predicts that Ke- suffer. In Botswana, 2-5% of teachers die others. In Africa the problem is dire. In nya's GDP will be 14.5% smaller in 2005 each year from AIDS. Many more take ex- Congo, where no fewer than seven armies than it would have been without AIDS, and tended sick leave. are embroiled, the government has accused that income per person will be 10% lower. At a macro level, the impact of AIDS is Ugandan troops (which are helping the felt gradually. But at a household level, the Congolese rebels) of deliberately spreading The cost of the disease blow is sudden and catastrophic. When a AIDS. Unlikely, but with estimated HIV In general, the more advanced the econ- breadwinner develops AIDS, his (or her) prevalence in the seven armies ranging omy, the worse it will be affected by a large family is impoverished twice over: his in- from 50% for the Angolans to an incredible number of AIDS deaths. South Africa, with come vanishes, and his relations must de- 80% for the Zimbabweans, the effect is its advanced industries, already suffers a vote time and money to nursing him. much the same. shortage of skilled manpower, and cannot Daughters are often forced to drop out of Sexism. In most poor countries, it is hard afford to lose more. In better-off developing school to help. Worse, HIV tends not to for a woman to ask her partner to use a con- countries, people have more savings to fall strike just one member of a family. Hus- dom. Wives who insist risk being beaten bands give it to wives, mothers to babies. AIDS, the killer This correspondent's driver in Kampala Life expectancy, years lost his mother, his father, two brothers and Africa, the target 70 Adults and children estimated to be living their wives to AIDS. His story is not rare. with HIV/AIDS, end 1998, m Botswana 65 Sub-Saharan South & South Africa 60 Obstacles to prevention Africa 22.5 South-East Asia 6.7 Swaziland The best hope for halting the epidemic is a South America & 55 cheap vaccine. Efforts are under way, but a Caribbean 1.73 Zimbabwe 50 vaccine for a virus that mutates as rapidly North America 0.89 45 as HIV will be hugely difficult and expen- Europe & 40 sive to invent. For poor countries, the only Central Asía 0.77 35 practical course is to concentrate on pre- East Asía & Australasia 0.57 s vention. But this, too, will be hard, for a 1993 94 95 96 97 plethora of reasons. North Africa & 98 Middle East 0.21 Sources: UNDP; US Bureau of the Census f'cast Sex is fun Many feel that condoms Sources: UNAIDS; WHO make it less so. Zimbabweans ask: "Would back on when they need to pay medical you eat a sweet with its wrapper on?" up. Rape is common, especially where wars bills. Where people have health and life in- and discussion of it often taboo. In Ke- rage. Forced sex is a particularly effective surance, those industries will be hit by big- nya, Christian and Islamic groups have means of HIV transmission, because of the ger claims. Insurers protect themselves by publicly burned anti-AIDS leaflets and con- extra blood. charging more or refusing policies to HIV- doms, as a protest against what they see as Drinking. Asia and Africa make many ex- positive customers. In Zimbabwe, life-in- the encouragement of promiscuity. A study cellent beers. They are also home to a lot of surance premiums quadrupled in two in Thailand found that infected women people for whom alcohol is the quickest es- years because of AIDS. Higher premiums were only a fifth as likely to have discussed cape from the stresses of acute poverty. force more people to seek treatment in pub- sex openly with their partners as were unin- Drunken lovers are less likely to remember lic hospitals: in South Africa, HIV and AIDS fected women. to use condoms. could account for between 35% and 84% of Myths abound. Some young African public-health expenditure by 2005, accord- women believe that without regular infu- How to fight the virus ing to one projection. sions of sperm, they will not grow up to be Pessimists look at that list and despair. But Little research has been done into the beautiful. Ugandan men use this myth to three success stories show that the hurdles effects of AIDS on private business, but the seduce schoolgirls. In much of southern Af- to prevention are not impossibly high. anecdotal evidence is scary. In some coun- rica, Hrv-infected men believe that they can First, Thailand. One secret of Thai- tries, firms have had to limit the number of rid themselves of the virus by passing it on land's success has been timely, accurate in- days employees may take off to attend fu- to a virgin. formation-gathering. HIV was first detected nerals. Zambia is suffering power shortages Poverty. Those who cannot afford televi- in Thailand in the mid-1980s, among male because so many engineers have died. sion find other ways of passing the evening. homosexuals. The health ministry immedi- Farmers in Zimbabwe are finding it hard to People cannot afford antibiotics, so the un- ately began to monitor other high-risk irrigate their fields because the brass fit- treated sores from STDS provide easy open- groups, particularly the country's many tings on their water pipes are stolen for cof- ings for HIV. heroin addicts and prostitutes. In the first fin handles. In South Africa, where employ- Migrant labour. Since wages are much half of 1988, HIV prevalence among drug ers above a certain size are obliged to offer higher in South Africa than in the sur- injectors tested at one Bangkok hospital generous benefits and paid sick leave, com- rounding region, outsiders flock in to find leapt from 1% to 30%. Shortly afterwards, in- panies will find many of their staff, as they work. Migrant miners (including South Af- fections soared among prostitutes. sicken, becoming more expensive and less ricans forced to live far from their homes) The response was swift. A survey of Thai productive. Yet few firms are trying to raise spend most of the year in single-sex dormi- sexual behaviour was conducted. The re- awareness of AIDS among their workers, or tories surrounded by prostitutes. Living sults, which showed men indulging in a considering how they will cope. with a one-in-40 chance of being killed by a phenomenal amount of unprotected com- In the public sector, where pensions rockfall, they are inured to risk. When they mercial sex, were publicised. Thais were and health benefits are often more gener- go home, they often infect their wives. warned that a major epidemic would strike THE ECONOMIST JANUARY 2ND 1999 43 AIDS IN THE THIRD WORLD if their habits did not change. A "100% con- barely literate. President Yoweri Museveni Contrast these three with South Africa. dom use" campaign persuaded prostitutes recognised the threat shortly after becom- On December 1st, World AIDS Day, Presi- to insist on protection 90% of the time with ing president in 1986, and deluged the dent Nelson Mandela told the people of non-regular customers. country with anti-AIDS warnings. KwaZulu-Natal that HIV would devastate By the mid-1990s, the government was The key to Uganda's success is twofold. their communities if not checked. The ending $80m a year on AIDS education First, Mr Museveni made every govern- speech was remarkable not for its quality- and palliative care. In 1990-93, the propor- ment department take the problem seri- Mr Mandela is always able to move audi- tion of adult men reporting non-marital ously, and implement its own plan to fight ences-but for its rarity. Unlike Mr Musev- sex was halved, from 28% to 15%; for the virus. Accurate surveys of sexual behav- eni, South Africa's leader seldom uses his women, it fell from 1.7% to 0.4%. Brothel vis- iour were done for only $20,000-30,000 authority to encourage safer sex. It is a tragic its slumped. Only 10% of men reported see- each. Second, he recognised that his govern- omission. Whereas the potholed streets of ing a prostitute in 1993, down from 22% in ment could do only a limited amount, so Kampala are lined with signs promoting fi- 1990. Among army conscripts in northern he gave free rein to scores of non-govern- delity and condoms, this correspondent Thailand, a group both highly sexed and mental organisations (NGOS), usually for- has, in eight months in South Africa, seen well-monitored, the proportion admitting eign-financed, to do whatever it took to only two anti-AIDS posters, both in the UN'S to paying for sex fell from 57% in 1991 to educate people about risky sex. AIDS office in Pretoria. 24% in 1995. The proportion claiming to The Straight Talk Foundation, for exam- have used condoms at their last commer- ple, goes beyond simple warnings about How to dither and die cial entanglement rose from 61% in 1991 to AIDS and deals with the confusing com- South Africa has resources and skills on a 93% in 1995. plexities of sex. Its staff run role-playing ex- scale that Uganda can only marvel at. It People lie about sex, so reported good ercises in Uganda's schools to teach adoles- even has an excellent AIDS prevention behaviour does not necessarily mean ac- cents how to deal with romantic situations. plan, accepted by the new cabinet in 1994. tual good behaviour. But tumbling infec- Its newsletter, distributed free, covers every- But the plan was never implemented. The tions suggest that not everyone was fibbing. thing from nocturnal emissions to what to government likes to consult every conceiv- The number of sexually transmitted dis- do if raped. Visiting AIDS workers from able "stakeholder", so new plans are eter- eases reported from government clinics fell South Africa and Zimbabwe asked the nally drafted and redrafted. Local authori- from over 400,000 in 1986 to under 50,000 foundation's director, Catharine Watson, ties cannot act without orders from the in 1995. Among northern conscripts, HIV how she won government permission to central government. NGOS, many of them prevalence fell by half between 1993 and hand out such explicit material, and were dependent on the powers-that-be for their 1995, from over 7% to under 3.5%. astonished to hear that she had not felt the finance, waste months making sure that Most striking was the government's suc- need to ask. enough of their senior management posts cess in persuading people that they were at The climate of free debate has led Ugan- are filled with blacks to satisfy the ruling Af- risk long before they started to see acquaint- dans to delay their sexual activity, to have rican National Congress. And they have ances die from AIDS. There was no attempt fewer partners, and to use more condoms. minimal freedom to experiment. to play down the spread of HIV to avoid Between 1991 and 1996, HIV prevalence "There's an idea that if you disagree scaring off tourists, as happened in Kenya. among women in urban ante-natal clinics with the government, you are betraying the Thais were repeatedly warned of the dan- fell by half, from roughly 30% to 15%. liberation struggle," says Mary Crewe, head gers, told how to avoid them, and left to Third, Senegal. If Uganda shows how a of the Greater Johannesburg AIDS project. make their own choices. Most decided that poor country can reverse the track of an epi- As a result, soldiers in the South African a long life was preferable to a fast one. demic, Senegal shows how to stop it from army are so ignorant that they snip the tips Second, Uganda. Thailand shows what taking off in the first place. This West Afri- off their free condoms, and HIV has spread is possible in a well-educated, fairly pros- can country was fortunate to be several through South Africa as fast, according to perous country. Uganda shows that there is thousand miles from HIV'S origin. In the Dr Neil McKerrow of Grey's Hospital in Pie- hope even for countries that are poor and mid-1980s, when other parts of Africa were termaritzburg, as if no preventive measures already blighted, Senegal was at all had been taken. still relatively AIDS-free. In Such bungling is not unique to South concert with non-govern- Africa. Most governments have been slow mental organisations and the to recognise the threat from AIDS. From Bu- press and broadcasters, the lawayo to Beijing, apathy and embarrass- government set up a national ment have hamstrung preventive efforts. AIDS-control programme to In anarchic countries, such as Congo keep it that way. and Angola, there have been almost no pre- In Senegal's brothels, ventive efforts. Many people believe that which had been regulated the cause-a bid to restrain one of the most since the early 1970s, condom basic human instincts-is hopeless. As a use was firmly encouraged. Zimbabwean novelist, Chenjerai Hove, The country's blood supply puts it with disturbing fatalism: "Since our was screened early and effec- women dress to kill, we are all going to die." tively. Vigorous education re- But if the sexual drive is basic, so is the de- sulted in 95% of Senegalese -sire to live. If governments in poor coun- adults knowing how to avoid tries wake up to the need to persuade their the virus. Condom sales citizens that unprotected sex is Russian soared from 800,000 in 1988 roulette, Mr Hove could be proved wrong. to 7m in 1997. Senegalese lev- els of infection have re- This article is indebted to a number of UNAIDS reports, mained stable and low for a including AIDS epidemic update (December 1998), AIDS in Africa (November 1998), and "A measure of success in decade-at around 1.2% Uganda" (May 1998). among pregnant women. 44 THE ECONOMIST JANUARY 2ND 1999 In Africa, a Deadly Silence About AIDS Is Lif. Page 1 of 6 NATIONAL FINDO COU. Science/Health The New York Times ON THE web IMUNIFIER NOW VC Home Site Index Site Search Forums Archives Marketplace ENTER Restau Movies Music Theater July 13, 1999 Bars & Art & ivi Books THE DOCTOR'S WORLD Sports Getawa In Africa, a Deadly Silence About AIDS SHOP Is Lifting Sales Events Coupo Related Articles Yellow The Dead Zones: AIDS in Africa Looking for the Light: The AIDS Epidemic CLASS Real E Forum Autos Jobs Join a Discussion on AIDS Epidemic COMM By LAWRENCE K. ALTMAN, M.D. About Join a Create E arlier this year, AIDS became the leading killer in Africa, a mere 18 years after the infection was first recognized. But if Update political and religious leaders had responded with effective LIFE public health programs much earlier, they might have prevented Food hundreds of thousands, if not millions, of deaths. Home Fashio Some leaders simply denied the scientific evidence that H.I.V. was Health How to being transmitted in their countries. Others mistakenly believed they had more pressing health problems to address. NEIGH Near M Now, as the epidemic in Africa Near M becomes an even greater catastrophe, Other A Dr. Peter Piot, Assistant Secretary General of the United Nations and head NEWYC of its AIDS programs, says he sees signs of momentum among African AD leaders to fight the disease. The momentum promises to slow the relentless transmission of H.I.V., conveyed on the continent primarily through heterosexual sex, Dr. Piot said in an interview. Nelson Mandela, the former President of South Africa; his successor, Thabo Ruby Washington/ The New York Mbeki, and Dr. Negasso Gidada, the . Times President of Ethiopia, are among the Dr. Peter Piot, the Assistant leaders of countries with high infection Secretary General in charge of the United Nations AIDS rates to speak out on AIDS for the first program, said he is finding a http://www.nytimes.com/library/national/science/aids/071399hth-doctors.html 7/13/99 In Africa, a Deadly Silence About AIDS Is Lif. Page 2 of 6 time recently in their own countries and program, said he is finding a new attitude toward the to put more money into prevention disease among African efforts. leaders. And, in May, at their annual meeting in Addis Ababa, Ethiopia, African finance ministers for the first time called AIDS a major threat to economic and social development. The United Nations General Assembly recently called for a 25 percent reduction in new H.I.V. infections among young people over the next five years in the countries most affected by AIDS. And the Clinton Administration, appalled by the staggering dimensions of the African AIDS epidemic, is planning an initiative to help, Dr. Piot said. Large-scale efforts clearly are needed. In sub-Saharan Africa, H.I.V. has infected 34 million people and killed 11.5 million since 1981, dwarfing malaria and tuberculosis. Last year, AIDS accounted for 1.8 million deaths in sub-Saharan Africa, nearly double the 1 million deaths from malaria and about nine times the 209,000 deaths from tuberculosis, according to Dr. Piot's agency, which has headquarters in Geneva. B ased on meetings with leaders of 10 African countries this year, Dr. Piot says he has noted a striking change in attitudes toward AIDS: at earlier meetings, he initiated discussions about AIDS; at the recent sessions, African leaders admitted their problems and asked for help. "It is such a big change," Dr. Piot, a 50-year-old Belgian and a pioneer in AIDS research in Africa, said in a brief visit to New York. In years past, Dr. Piot said, even meeting with an African head of state was difficult. He recalled an incident about 15 years ago when he and another AIDS expert waited nearly a day in the office of the Kenyan Minister of Health while officials debated whether to expel the two because they had talked to reporters about AIDS in Kenya. In 1985, Zaire refused to give me a visa to report on AIDS, and the Government of Kenya confiscated issues of The International Herald Tribune, which carried my articles, because of its displeasure with my coverage of AIDS there. African political leaders remained silent even when AIDS was killing members of their own families. In 1985, the press secretary to Kenneth D. Kaunda, then the President of Zambia, denied my request for an interview about AIDS. The press secretary threatened to expel me for reporting on what he called an American disease. A year later, Kaunda lost a son to AIDS. http://www.nytimes.com/library/national/science/aids/071399hth-doctors.html 7/13/99 In Africa, a Deadly Silence About AIDS Is Lif. Page 3 of 6 In 1989, Kaunda was one of the first to speak out. In describing his family's loss at an international AIDS meeting in Montreal, Kaunda said that if scientists failed to cure AIDS, the epidemic would become "a soft nuclear bomb on human life." But in the years of Kaunda's silence, hundreds of thousands of Africans became infected. Yet even now realism has not fully set in. Dr. Piot still encounters government officials who "ask why I use the word epidemic," he said. t takes an average of nine years for H.I.V. to progress to AIDS, and the virus spread widely and silently for a decade before being discovered. Yet even with the undetected early spread, there was time to initiate programs to prevent subsequent infections, as was done effectively among gay men in the United States and other developed countries. In South Africa, H.I.V. rates soared during Nelson Mandela's Administration, a fact that he later acknowledged. "It's the silence that is letting this disease sweep through the country," Mandela said on World AIDS Day in December. "It is time to break the silence." Dr. Piot applauded Mandela and Mbeki, his successor, for calling national attention to AIDS, but said, "It took a long time, and a lot of deaths could have been prevented if they had spoken out earlier." Today, AIDS continues to thin the ranks of Africa's small middle class, killing at least one teacher a day in Malawi and the Ivory Coast. It is devastating already weak economies across Africa and forcing children to drop out of school to till the farms and care for sick parents. Dr. Piot challenged African finance ministers at their annual meeting in Addis Ababa in May to learn more about how AIDS was devastating their economies. "After my speech, there was dead silence," Dr. Piot said. "I thought, another of those moments of supreme denial." But then, he added, "One after the other, the finance ministers spoke, often making personal references to AIDS in the family or a colleague." That evening, many joined him for a drink. "The problem was how to stop the discussions," Dr. Piot said. "That was a great moment for me." The next day, Dr. Gidada, the President of Ethiopia, and His Holiness Abune Paulos, the Patriarch of the Ethiopian Orthodox http://www.nytimes.com/library/national/science/aids/071399hth-doctors.html 7/13/99 In Africa, a Deadly Silence About AIDS Is Lif. Page 4 of 6 Church, shook hands as they met publicly for the first time with H.I.V.-infected Ethiopians, Dr. Piot said. "That may have been a small thing, but it was highly symbolic in Africa," he added. Yet it was a gesture that political leaders elsewhere had made in the 1980's. Uganda, which acted early, showed that educational programs could change sexual behavior after AIDS had struck in vast numbers. Senegal and Brazil also thwarted the assault of AIDS, Dr. Piot said, taking "vigorous action" on sex education, AIDS prevention and condom promotion to keep the infection rate below 2 percent. "It is a major political challenge to invest in AIDS prevention when there is not a huge problem," Dr. Piot said, "yet that is exactly what Senegal has done." Through programs that political and religious leaders encouraged, the Senegalese postponed having first sexual intercourse, used condoms more often and had sex with fewer partners and less sex with prostitutes, surveys there showed. Nigeria, Africa's most populous country, stands in stark contrast, with an infection rate of about 9 percent and rising. A new regime appears to be willing to tackle the AIDS problem in Nigeria, which the previous regime denied, Dr. Piot said. D r. Piot's team has a budget of $60 million a year, only enough to act as a catalyst for others to undertake prevention efforts. His AIDS team, for example, calls on African leaders to urge drastic efforts to fight the epidemic. The latest figures show that international aid paid for $150 million of the $165 million spent on AIDS prevention in Africa in 1997. Uganda accounted for much of the $15 million that the African countries spent. "It's a scandal that African countries have not spent more," Dr. Piot said. Although the World Bank and other international agencies make money available for projects in Africa, much of it goes unspent because of bureaucratic complexities and other problems. Dr. Piot said his agency was trying to identify untapped funds to direct toward prevention efforts, while recognizing that those nations "cannot afford everything for AIDS, certainly not lifetime anti-retroviral drugs." Taken in combination, those drugs can cost $15,000 a year for a single patient, require adherence to rigid schedules, and often demand sophisticated monitoring tests unavailable in developing countries. That means few Africans can benefit from the drug http://www.nytimes.com/library/national/science/aids/071399hth-doctors.html 7/13/99 In Africa, a Deadly Silence About AIDS Is Lif... Page 5 of 6 cocktails, which are prolonging lives and often restoring health among H.I.V.-positive people in developed nations. To reach a largely captive audience, and one in its sexual prime, Dr. Piot is encouraging governments to spend more of their military budgets, which usually receive high priority, on AIDS prevention. In Uganda, the infection rate is about 10 percent in the general population and up to 30 percent in the military. "There are African countries where it is said that more than 50 percent of all the military are H.I.V. infected," Dr. Piot said, "and that is a problem of national security." It also means that many spouses and children are infected. So Dr. Piot's team aims to encourage teachers' unions, school systems and youth groups to join prevention programs in Africa. In some West African countries, for example, Scouting groups have created an AIDS badge for those who do good deeds for people with H.I.V., Dr. Piot said. His agency has also teamed on AIDS efforts with Caritas, a Catholic health agency based in the Vatican that is responsible for health care in many African countries, Dr. Piot said. Although the Vatican does not approve of the use of condoms, Dr. Piot said that he had seen many Catholic priests, nuns and organizations promote condom use in Africa. n June 1998, Dr. Piot's agency issued the first country-by-country analysis of H.I.V. It showed that one in four adults was infected with H.I.V. in certain parts of Africa and that AIDS was hitting so fiercely that it compared to the greatest epidemics of history. The report was a crucial factor in changing political attitudes, Dr. Piot said. Dr. Piot said he was criticized for the report by many Western epidemiologists and health workers, who called the figures exaggerated. "A lot of the criticism had to do with turf battles, from scientists who believe their disease is more important than someone else's," Dr. Piot said, "and it's the type of nonsensical competition that exists in all countries." But now, the criticism has come full circle. In 1992, a team headed by the late Dr. Jonathan M. Mann at the Harvard School of Public Health, published estimates of H.I.V. infections in sub-Saharan Africa ranging from 20.8 million to 33.6 million by 2000. The World Health Organization criticized Dr. Mann's estimates as excessive. Now, academic scientists are criticizing the figures of Dr. Piot's team. "When we look at the figures today, they are http://www.nytimes.com/library/national/science/aids/071399hth-doctors.html 7/13/99 In Africa, a Deadly Silence About AIDS Is Lif. Page 6 of 6 worse than the scenarios Jonathan had published," Dr. Piot said. L arger budgets are needed. But pumping money into a country where AIDS is a low priority will not end the epidemic. "If a country does not recognize that it has an AIDS problem, then it is not willing to take on the tough questions," Dr. Piot said. "Outside support for something that can only be solved from the inside will not work. "We can only win," he added, "if there is a mass movement." Home I Site Index I Site Search I Forums I Archives I Marketplace bick News I Page One Plus I International I National/N.Y. I Business I Technology I Science I Sports I Weather I Editorial I Op-Ed I Arts I Automobiles I Books I Diversions Job Market I Real Estate I Travel Help/Feedback I Classifieds I Services I New York Today Copyright 1999 The New York Times Company http://www.nytimes.com/library/national/science/aids/071399hth-doctors.html 7/13/99 ANNEX 2. HIV/AIDS PREVALENCE RATES FOR SSA Adult (15-49 Years) HIV/AIDS Prevalence Rates, Sub-Saharan Africa, December 1997 Rank Country Adult HIV/AIDS Rank Country Adult HIV/AIDS rate (percent) rate (percent) 1 Zimbabwe 25.84 23 Democratic Republic 4.35 of Congo 2 Botswana 25.10 24 Gabon 4.25 3 Namibia 19.94 25 Nigeria 4.12 4 Zambia 19.07 26 Liberia 3.65 5 Swaziland 18.50 27 Eritrea 3.17 6 Malawi 14.92 28 Sierra Leone 3.17 7 Mozambique 14.17 29 Chad 2.72 8 South Africa 12.91 30 Ghana 2.38 9 Rwanda 12.75 31 Guinea-Bissau 2.25 10 Kenya 11.64 32 Gambia, The 2.24 11 Central African 10.77 33 Angola 2.12 Republic 12 Djibouti 10.30 34 Guinea 2.09 13 Côte d'Ivoire 10.06 35 Benin 2.06 14 Uganda 9.51 36 Senegal 1.77 15 Tanzania 9.42 37 Mali 1.67 16 Ethiopia 9.31 38 Niger 1.45 17 Togo 8.52 39 Equatorial Guinea 1.21 18 Lesotho 8.35 40 Mauritania 0.52 19 Burundi 8.30 41 Somalia 0.25 20 Republic of Congo 7.78 42 Comoros 0.14 21 Burkina Faso 7.17 43 Madagascar 0.12 22 Cameroon 4.89 44 Mauritius 0.08 Note: Adult rates (percent) are derived from the number of adults (15-49 years) living with HIV/AIDS at the end of 1997 divided by the 1997 adult population. Source: UNAIDS, 1998a. 56